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Abstract 
The function of a protein or peptide is governed by its unique secondary structure and intrinsic 
dynamic properties. Hence, an ability to control secondary structure and an understanding of its 
dynamic behavior would allow for the regulation of protein function. However, proteins exhibit 
conformational complexity, which impedes a thorough investigation of the relationship between 
structure and function. Thus, model peptides present as ideal candidates for this purpose. 
Research undertaken in this thesis aims to control the secondary structure and hence, peptide 
activity, in addition to probing the intrinsic dynamic properties corresponding to specific 
structural changes within peptides. This research deepens our understanding of the secondary 
structure and the underlying dynamic properties of peptides, with these fundamental behaviors 
potentially transcending to proteins, which may provide important insights into their functions.  
Chapter one provides an overall introduction to the importance of secondary structure in 
proteins/peptides, and the structural dynamic behavior that governs protein function. Various 
strategies are introduced to control the secondary structure and antibacterial activity of peptides, 
along with the single-molecule junction technique used to probe the structural dynamic 
properties of peptides.  
Chapter two presents the photopharmacological approach to regulate secondary structure, and 
hence, antibacterial activity of a series of gramicidin S peptide mimetics through the 
photochemical control of a component azobenzene photoswitch. Detailed 1H NMR 
spectroscopy and density functional theory (DFT) calculations were used to define the 
secondary structure in the cis and trans configurations of the peptides, and both isomers of all 
peptide mimetics were assayed against S. aureus. Notably, peptides 2a and 2b were found to 
exhibit a four-fold difference between the cis-enriched and trans-enriched photostationary 
states. This study revealed a clear relationship between well-defined secondary structure, 
amphiphilicity, and optimal antibacterial activity. 
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Chapter three describes the design and synthesis of three short photoswitchable tetrapeptides 
based on a known synthetic antibacterial. Each peptide contains an azobenzene photoswitch 
incorporated into either the N-terminal side chain, C-terminal side chain, or the C-terminus, to 
allow reversible switching between the cis and trans configurations. The C-terminus 
azobenzene (3) exhibited the most potent antibacterial activity against S. aureus, with an MIC 
of 1 μg/mL. A net positive charge, hydrophobicity, position of the azobenzene, secondary 
structure, and amphiphilicity were all found to be crucial to antibacterial activity.  
Chapter four reports a prodrug based on a known antibacterial compound to target S. aureus 
and E. coli under reductive conditions. The prodrug was synthesized by masking the N-terminus 
and side chain amines of a component lysine residue as 4-nitrobenzyl carbamates, while 
activation of the prodrug was achieved by removing the protecting groups under conditions that 
mimic hypoxia. Antibacterial susceptibility assays confirmed the liberation of the active 
antibacterial agent from the inactive prodrug to kill S. aureus and E. coli. 
Chapter five investigates the structural dynamic properties of a single-peptide using the single-
molecule junction technique characterized by electrical conductance. The nanodevice was 
fabricated using a photoswitchable peptide containing an azobenzene photoswitch to provide 
both a well-defined secondary structure, and an intrinsically disordered structure. Real-time 
conductance measurements revealed three distinct states for each isomer, with molecular 
dynamics simulations showing each state corresponds to a specific range of hydrogen bond 
lengths within the cis isomer, and specific dihedral angles in the trans isomer. This study 
provides previously undisclosed insights into the structural dynamic behavior of peptides, which 
may well be applicable to proteins.  
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1.1 Importance of secondary structure in proteins / peptides 
Peptides consist of a short chain of amino acids, with the most fundamental being dipeptides, 
tripeptides, and tetrapeptides. Long linear chains of amino acid residues are known as 
polypeptides, which can fold to give a well-defined and functional three-dimensional structure. 
Proteins can adopt four levels of structure, namely primary, secondary, tertiary, and quaternary. 
The primary structure of a protein is defined by the unique amino acid sequence, which then 
folds into secondary structures that are stabilized by hydrogen bonds between the amide CO and 
NH groups of the repeating constituents on the polypeptide backbone.1 The two main types of 
secondary structures for peptides/proteins are α-helices and β-strands. These secondary 
structures can aggregate into a three-dimensional tertiary structure, stabilized by interactions 
between the side chains of amino acid residues that constitute the polypeptide. These side chain 
interactions include hydrogen bonding, ionic bonding, dipole-dipole interactions, hydrophobic 
interactions, and disulfide bonds.2 Two or more polypeptide chains, known as subunits, can then 
assemble to form a protein with a quaternary structure. A well-defined secondary structure in 
the hierarchical classification of protein structure is of significant interest as it provides a basis 
for fold recognition.3 The protein fold is the unique geometric arrangement of structural motifs 
in space, and its identification is essential in determining protein structure and function.4 For 
example, enzymes are proteins containing secondary structures that fold into a globular 
conformation for catalytic activity, while the structural protein collagen possesses an extended 
helical conformation to maintain cell rigidity.5 These protein structures highlight the importance 
of secondary structure as fundamental structural elements that define the overall protein 
architecture and function. Thus, an ability to control the secondary structure of a protein would 
allow modulation of protein function. Since the structure and conformation of proteins is 
incredibly complex, alternative means such as model peptides are commonly used to study the 
relationship between structure and function.6 
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1.1.1 α-helix, β-strand, β-sheet, and β-turn secondary structures 
An α-helix is formed when the linear sequence of amino acids is tightly coiled around the long 
axis of the peptide, with the side chains of component amino acid residues projecting outward 
from the helical backbone (Figure 1.1a).2 The α-helix is the most abundant form of secondary 
structure in proteins.7 A right-handed helix consists of 3.6 residues per turn, which is stabilized 
by intramolecular hydrogen bonds between each amide CO (i) and NH (i + 4) on the peptide 
backbone (Figure 1.1b).8 The ideal dihedral angles for an α-helix are, Φ = -60° and Ψ = -45° 
(Figure 1.1c).8  
 
Figure 1.1. The α-helix secondary structure. (a) Side view of an α-helix model, showing the side chains 
of the amino acid residues projecting outward from the peptide backbone.8 (b) The α-helix is stabilized 
by intramolecular hydrogen bonds between the amide CO (i) and NH (i + 4) groups on the peptide 
backbone.9 (c) Schematic diagram of dihedral angles in a peptide backbone. Phi (Φ) indicates the rotation 
between the N-Cα bond, while psi (Ψ) indicates the rotation between the Cα-CO bond. 
Work in this thesis is primarily concerned with peptides containing a β-strand, which is an 
extended arrangement of amino acids folded to form a pleated structure, with the distance 
between adjacent amino acid residues along the strand approximately 3.5 Å.10 A β-sheet, formed 
by two or more β-strands connected via hydrogen bonding (Figure 1.2a), comprises more than 
30 % of all protein structures.11 It is described as parallel when both strands are running in the 
same direction, while two aligned strands running in the opposite direction are termed 
antiparallel. The amide CO and NH groups in a β-strand are situated orthogonal to the backbone, 
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thus reducing steric hindrance between the side chains (Figure 1.2b). Ideal dihedral angles for 
the peptide backbone are Φ = -119°, Ψ = 113° for a parallel β-sheet, and Φ = -139°, Ψ = 135° 
for an antiparallel β-sheet.11 A β-turn secondary structure is produced when a peptide chain 
reverses its overall direction, folding into a β-hairpin motif that is stabilized by intramolecular 
hydrogen bonds (Figure 1.2c).12 The β-turn is the third most important secondary structure after 
α-helices and β-strands, comprising 25-30 % of all protein structures.13 There are eight different 
types of β-turns, each of which are defined by the values of Φ and Ψ dihedral angles of the 
corner residues, i + 1 and i + 2.13 The amino acids with a strong turn-forming propensity, such 
as DPro-Gly, DPhe-Pro, and Aib-DPro, are known to promote the formation of β-turn and β-
hairpin secondary structures that are commonly found in cyclic peptides.14 
The β-strand, β-sheet, and β-turn secondary structures provide key recognition motifs for 
protein-protein interactions to mediate various biological processes.15 For example, the 
regulation of signal transduction by G protein-coupled receptors (GPCR) requires 
heterodimerization between rhodopsin and arrestin through β-strand domains, forming an 
extended network of antiparallel β-sheets to modulate downstream signaling effectors.16 Figure 
1.3 shows the crystal structure of the rhodopsin-arrestin complex, which is stabilized by 
electrostatic interactions, hydrogen bonding, and disulfide cross-linkages. Moreover, immune 
system regulation by toll-like receptors (TLR)17 and binding interactions between cell adhesion 
molecules, CD2 and CD58,18 also require β-strand, β-sheet, or β-turn/hairpin secondary 
structures, highlighting their importance for protein-protein interactions. This thesis presents the 
synthesis of a series of peptides that adopt a β-strand geometry, and then an investigation into 
associated biological activity and structural dynamic properties as described in each chapter. 
For example, the cyclic peptide gramicidin S contains a β-sheet comprising two antiparallel β-
strands, linked by two β-turns, which are crucial to its antibacterial property. This antibacterial 
peptide is considered further in the following section, and also in chapter 2. 
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Figure 1.2. β-strand, β-sheet, and β-turn secondary structures. (a) Schematic diagram of a parallel (top) 
and an antiparallel (bottom) β-sheet, consisting of two β-strands linked by intermolecular hydrogen 
bonds, indicated by dashed lines. Arrows represent the direction from N- to C-terminus. (b) A β-strand 
showing the amide CO (red) and NH groups (blue) situated orthogonal to the peptide backbone, thus 
minimizing steric hindrance between the side chains. (c) Ribbon representation of a β-turn induced by 
the corner residues, i + 1 and i + 2, folding into a β-hairpin motif that is stabilized by intramolecular 
hydrogen bonds, indicated by dashed lines.14  
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Figure 1.3. Crystal structure of the rhodopsin-arrestin complex. (a) The C-terminus tail of rhodopsin 
(green) dimerizes with the N-terminus of arrestin (brown) through the β-strand domains, forming an 
extended network of antiparallel β-sheets to mediate specific cell signaling pathways. Inset shows the 
enlarged section of the antiparallel β-sheet. (b) Docking structure of the rhodopsin-arrestin complex, 
showing the electrostatic interactions between the β-strand domains of rhodopsin and arrestin.16 
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1.1.2 Antibacterial peptide gramicidin S 
Gramicidin S, a natural antibiotic isolated from soil bacterium Bacillus brevis,19 is a cyclic 
decapeptide [cyclo(DFPVOL)2, where 
DF=D-phenylalanine, O=ornithine] with a symmetrical 
antiparallel β-sheet conformation, linked by two type-II’ β-turns (Figure 1.4).20 The β-sheet 
secondary structure in gramicidin S is stabilized by four strong intramolecular hydrogen bonds 
between the two β-strands, with bond lengths ranging between 2.0-2.2 Å.20 The antibacterial 
properties of gramicidin S have been attributed to its well-defined secondary structure and its 
overall amphiphilic nature.21 Specifically, the side chain amines of the ornithine residues can be 
protonated to carry positive charges, while the remaining amino acid residues form a surface 
with a hydrophobic membrane core.22 This amphiphilic nature allows gramicidin S to establish 
electrostatic interactions for binding onto negatively charged bacterial outer membranes, and 
induces further disruption on inner lipid membranes.23 The bacterial membrane is essential for 
many metabolic functions, including transport, osmoregulation and respiration processes, 
biosynthesis and cross-linking of peptidoglycan, and synthesis of lipids.24 Thus, any disruption 
of the bacterial membrane will trigger metabolic dysfunction and ultimately lead to cell death.24 
The detailed mechanism of action for gramicidin S is not clearly understood, and it remains 
controversial. Previous studies have proposed that following binding, gramicidin S induces pore 
formation in a detergent-like manner, leading to the disintegration of the bacterial membrane.24 
However, more recent studies revealed a more multifaceted and complex mechanism, where 
gramicidin S destabilizes the bacterial membrane by regulating certain membrane proteins.25-26 
Gramicidin S displays superior activity against a broad spectrum of Gram-positive and Gram-
negative bacteria,27 and is less susceptible to resistance due to its preferential disruption of the 
bacterial membrane,28 and multiple modes of antibacterial action.25-26 Thus, gramicidin S 
presents as a promising alternative to treat multidrug-resistant bacteria that pose a worldwide 
threat to public health. Although gramicidin S serves as a potent antibiotic, it also exhibits 
hemolytic effects, bringing with it unknown safety and toxicity concerns for oral administration. 
Hence, in its natural form, it has limited therapeutic value apart from topical application.27, 29 
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Figure 1.4. The natural antibacterial peptide gramicidin S. (a) Chemical structure of gramicidin S, 
stabilized by four intramolecular hydrogen bonds (dashed lines). (b) Model structure of gramicidin S 
(side view), highlighting the β-sheet conformation. (c) Scanning Electron Microscope (SEM) image 
showing the disruption of S. aureus bacterial membrane by gramicidin S.24   
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Inspired by the promising antibacterial properties of the naturally occurring gramicidin S 
peptide, a number of studies have been conducted to design and develop gramicidin S peptide 
mimetics with reduced side effects. The Hodges, Overhand, and Tamaki research groups each 
modified the ring size of gramicidin S, which had an impact on the β-sheet content, 
amphiphilicity, hydrophobicity, and thus, antibacterial activity of the peptide mimetics.30-32 
Moreover, several other groups modified the β-turn region of gramicidin S by replacing the 
corner residues (DPhe-Pro) with dipeptide surrogates.27, 33 A recent study by the Valérie group 
reported the design and synthesis of a diastereomeric pair of gramicidin S peptide mimetics 
using β,γ-diamino acids to mimic the β-turns (Figure 1.5), which exhibited moderate 
antibacterial property, with significantly diminished hemolytic activity.34 Other basic design 
principles for gramicidin S peptide mimetics include changing the overall charge of the peptide, 
inducing secondary structure, altering the ratio of hydrophobic and hydrophilic residues, and 
improving the peptide amphiphilicity.35-36 Furthermore, numerous synthetic peptides have been 
reported to target specific bacteria based on combinatorial library approaches.37-38 Despite the 
superior activity of many gramicidin S peptide mimetics and related synthetic peptides, their 
clinical application remains limited due to high toxicity in vivo and lability toward proteases.39 
Hence, other strategies are required to enhance bioavailability as developed further in this thesis.  
 
Figure 1.5. Chemical structures for the diastereomeric pair of gramicidin S peptide mimetics developed 
by the Valérie group using β,γ-diamino acids to mimic the β-turns.34  
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1.1.3 Controlling peptide secondary structure and antibacterial 
activity through photopharmacology and hypoxia activation 
Photopharmacology is an emerging strategy to modulate the bioactivity of a compound using 
light of a specific wavelength (Figure 1.6).40-41 In the case of an antibacterial peptide, this would 
allow reversible control of its secondary structure to modulate antibacterial activity. Light 
provides an ideal means to regulate bioactivity as the timing, location, and intensity of 
irradiation can be fine-tuned to allow localized treatment of an associated disease.42-44 This 
approach also offers an opportunity to mitigate off-target side effects, and in the context of an 
antibiotic, the development of resistance.45-46 Photocontrol is achieved by incorporating a 
reversible molecular switch (photoswitch) into the compound, which is interconverted between 
two isomeric forms upon photoisomerization using light of a specific wavelength.47 
Photoisomerization induces changes in both physical and chemical properties, thus enabling 
reversible ‘on’ and ‘off’ regulation of activity. Previous studies have demonstrated the use of 
various photoswitches, such as azobenzene,48-49 stilbene,50-51 thioxylated amide,52 
fumaramide,53 hemithioindigo,54-55 diarylethene,56-57 spiropyran,58-59 and overcrowded alkene60 
to control the secondary structure and hence, activity of peptides (Figure 1.7). The most well-
known of these is the azobenzene photoswitch.  
The discovery of azo compounds (–N=N–) in the mid-1800s instigated the development of 
synthetic coloring agents in the dye and pigment industry.61 An example of azo derivatives is 
the azobenzene molecule, with its photochromic properties revealed upon exposure to light.62 
Extensive studies have been performed on azobenzene, making it among the best characterized 
photoswitch.63-64 Azobenzene can be reversibly interconverted between the cis and trans 
configurations using light of specific wavelengths,65 which produces significant structural 
changes.66-68 The trans isomer adopts an extended near planar structure, and is 
thermodynamically more stable than its ‘bent’ counterpart, the cis isomer, by approximately 50 
kJ/mol.65, 67 The distances between two specific carbon atoms located at the para position of 
each phenyl ring of an unsubstituted azobenzene are ~9.0 Å and ~5.5 Å for the trans and cis 
isomers respectively.69 This large difference in spatial arrangement gives rise to the distinctive 
physical and chemical properties of each isomer. The trans isomer of an unsubstituted 
azobenzene has no dipole moment, while its cis counterpart possesses a dipole moment of 3 
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Debye.70 The absorbance spectra for each isomer are distinct, yet display some slight overlap. 
Specifically, the trans isomer exhibits an intense absorbance band around 320 nm due to the 
π→π* transition.71-74 In contrast, the cis isomer shows a significantly less intense absorbance 
around 320 nm, with a weak absorbance around 420 nm due to the forbidden n→π* transition.71-
74 Conversion of the trans to cis isomer using UV light (320 nm) provides a photoisomerization 
yield of approximately 80%, whereas ~99% conversion of the cis to trans isomer is attainable 
through visible light or heat.70, 75 The photoswitching of azobenzene using highly ionizing UV 
light limits the application of azobenzene in biological systems. Thus, numerous studies have 
been conducted in an attempt to shift the photoswitchable wavelength of azobenzene into the 
visible light or infrared regions that are more compatible with biological systems.76-78 
Nevertheless, azobenzene is the most commonly used class of photoswitch for the photocontrol 
of biomolecules79 due to its many advantages such as high quantum yield,70 fast isomerization,70, 
80 low rate of photobleaching,74 and relative ease of synthesis.70, 80 The Abell group has 
demonstrated the incorporation of an azobenzene photoswitch into peptides to control the 
activity of antibiotics,81 biosensors,82 protease inhibitors,83-85 and smart membranes.86 Figure 
1.8 shows the photoswitchable peptide-based biosensor containing an azobenzene photoswitch, 
modelled on the neuronal nitric oxide synthase (nNOS) β-hairpin ligand to detect and control 
its interaction with α-syntrophin protein. The azobenzene photoswitch allows photochemical 
control of the secondary structure, enabling switching between a random configuration (trans) 
and a well-defined β-strand geometry (cis) that mimics the β-hairpin motif of native nNOS, to 
facilitate binding to the PDZ domain of α-syntrophin.82 
An alternative method to control the activity of antibacterial peptides is a hypoxia-activated 
prodrug strategy. Tissue hypoxia is a common microenvironmental hallmark associated with 
bacterial infection, with low levels of oxygen caused by reduced blood supply to the infected 
tissue.87 Hence, hypoxia-activated prodrugs present as an attractive strategy to regulate the 
activity of an antibiotic, such that the active agent is only released under conditions of low 
oxygen, as found in specific bacterial-infected tissues.88-89 These prodrugs are designed by 
masking the warhead with a protecting group, which is reduced under hypoxic conditions to 
produce the corresponding active form for a directed therapeutic effect.90 This particular 
approach limits general exposure to the active agent, thereby mitigating possible undesirable 
side effects. Importantly, it improves the selectivity of drug delivery as the antibacterial is only 
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activated at the site of infection, which can potentially lead to the suppression of antibiotic 
resistance. Figure 1.9 illustrates the mechanism of reductive activation for a particular hypoxia-
activated prodrug, Evofosfamide (TH 302), which contains a 2-nitroimidazole protecting group. 
The reductase mediates one-electron reduction of the prodrug to produce a radical anion.90 In 
the presence of oxygen, the unpaired electron in the radical anion is rapidly scavenged by 
molecular oxygen to regenerate the prodrug, resulting in a futile cycle.90 Conversely, in a 
hypoxic environment, the radical anion will be reduced further, inducing fragmentation to 
release the active drug for, in this case, anticancer activity.90 This concept has been widely 
employed in cancer research to design and synthesize hypoxia-activated prodrugs,91-93 and a 
number of these prodrugs are currently undergoing clinical studies as they have demonstrated 
great promise for targeted therapy.94 However, hypoxia-activated prodrug strategies for 
bacterial-infected tissue are in their infancy, thereby signifying the need for future fundamental 
research in this area.  
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Figure 1.6. Differences between conventional delivery of a bioactive compound and 
photopharmacology. (a) Conventional delivery of a bioactive compound causes off-target side effects 
due to the non-selective toxicity. (b) Reversible switching between the inactive (blue) and active (red) 
compound using light of a specific wavelength. (c) The photopharmacological approach reversibly 
activates the inactive compound to allow localized treatment and targeted toxicity upon irradiation using 
light of a specific wavelength. (Figure adapted from Szymanski et al.43) 
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Figure 1.7. Chemical structures of various photoswitches used in photopharmacology, showing 
photoisomerization using light of a specific wavelength. (a) Azobenzene. (b) Stilbene. (c) Thioxylated 
amide. (d) Fumaramide-maleamide. (e) Hemithioindigo. (f) Diarylethene. (g) Spiropyran-merocyanine. 
(h) Overcrowded alkene. 
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Figure 1.8. Photoswitchable peptide-based biosensor containing an azobenzene photoswitch, modelled 
on the β-hairpin region of neuronal nitric oxide synthase (nNOS).82 (a) The large spatial dissimilarity 
between the trans (left) and cis (right) configurations. The azobenzene in its cis configuration mimics 
the β-hairpin motif of nNOS, producing a cyclic peptide with a well-defined β-strand geometry for 
binding to the PDZ domain of the α-syntrophin protein. In contrast, the ill-defined trans configuration 
does not allow binding to α-syntrophin. (b) Crystal structure showing the well-defined β-strand and β-
hairpin secondary structures of native nNOS for binding to the PDZ domain of the α-syntrophin protein.95 
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Figure 1.9. Reductive activation of a hypoxia-activated prodrug, Evofosfamide (TH 302), which 
contains a 2-nitroimidazole protecting group (purple). The reductase mediates one-electron reduction of 
the prodrug to form a radical anion. In well-oxygenated tissue, the unpaired electron of the radical anion 
will be rapidly scavenged by molecular oxygen to regenerate the prodrug, resulting in a futile cycle. In 
contrast, the prodrug radical anion will be reduced further and fragmented to trigger an anticancer effect 
under a hypoxic environment.90  
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1.2 Dynamic behavior of proteins / peptides 
All proteins are dynamic structures96 that undergo random thermal fluctuations and 
conformational changes to regulate a complex network of molecular recognition and interaction 
for a multitude of biological processes.15, 97 The dynamic nature of proteins indicates that merely 
probing the secondary structural elements does not adequately provide all crucial information 
needed to understand protein function, as protein behavior and properties stem from protein 
dynamics.98-99 Indeed, in a growing number of cases, cellular functions are defined by 
intrinsically disordered proteins, which can fold into well-defined complexes upon binding to 
their ligands to perform a specific function.100-104 The functional role of such intrinsically 
disordered proteins is acknowledged in areas such as transcriptional regulation,105 translational 
regulation,106 and cellular signal transduction,107 thus demonstrating the importance of 
flexibility for such transient interactions. Moreover, structural plasticity also enables these 
intrinsically disordered proteins to interact with multiple binding partners to optimize 
function.108 Hence, understanding protein function requires comprehensive studies on the 
structural and dynamic properties (structural dynamics) of proteins. However, the structural 
dynamic properties of proteins cannot be fully elucidated under equilibrium conditions,99 such 
as X-ray crystallography, as this approach only provides a snapshot of the peptide frozen in 
crystal structures.98 To further our understanding of structured/unstructured proteins in motion, 
sophisticated biophysical instrumentation is required to measure the physical properties from 
which their structural dynamic behavior can be inferred. Moreover, it is extremely challenging 
to probe the intrinsic structural dynamic properties of proteins due to their conformational 
complexity.109 Thus, a model peptide containing a well-defined secondary structure, able to be 
controlled by such strategies as those discussed in section 1.1.3, presents as an ideal candidate 
to probe the structural dynamic behavior of peptides. Exercising control over the secondary 
structure allows for detection and measurement of the physical properties that are specific to 
each peptide conformation, providing insights into the structural dynamic behavior that governs 
protein/peptide function.  
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1.2.1 Probing the structural dynamic behavior of peptides through 
single-molecule junctions  
The single-molecule junction method provides an ideal platform to probe the structural dynamic 
behavior of peptides, as it allows ultrasensitive detection and measurement of the structural 
dynamic properties of peptides in real-time, with single-bond resolution (Figure 1.10). A typical 
single-molecule junction comprises a molecule bridged between a pair of nanogapped metal or 
graphene electrodes. The single-molecule contains anchoring groups, for example, amine (–
NH2), thiols (–SH), and fullerenes on its termini or side chains, to allow coupling to 
functionalized electrodes via donor-acceptor (dative) interactions, or through covalent 
bonding.110-111 In general, covalent linkages are more stable than dative bonding due to greater 
bond strength.112 The working concept of a single-molecule junction involves detecting the 
biophysical changes induced by an external stimulus such as light, temperature, magnetic field, 
biological interaction, and chemical stimulus, which are then transduced into measurable 
signals.113 These signals can be characterized using microscopic, electrical, optical, or 
optoelectronic techniques,114 which allow direct observation of novel phenomena such as the 
Kondo effect, negative differential resistance, and Coulomb blockade.115 Moreover, the single-
molecule junction enables the discovery of intrinsic physical properties of materials (e.g., 
structural dynamics) that are not accessible in bulk molecular crystals using conventional 
means.116-117 Hence, several experimental techniques have been developed to fabricate and 
study single-molecule junctions, including mechanically controllable break junctions 
(MCBJs),118-120 atomic force microscopy (AFM),121-122 electromigration,123-124 scanning 
tunneling microscopy break junctions (STM-BJ),121, 125-126 and oxidative lithography (Figure 
1.11). The Guo group demonstrated the establishment of a graphene-molecule-graphene single-
molecule junction (GMG-SMJ) (Figure 1.12) to study a range of fundamental chemical 
processes including hydrogen bond dynamics,127 nucleophilic substitution reaction,128 
conductance switching,129-131 and charge transport,132-133 thus highlighting the robustness and 
versatility of this technique. The fabrication of a GMG-SMJ begins with the growth of single-
layered graphene on copper foils via chemical vapor deposition (CVD). The graphene films are 
then transferred onto the SiO2/Si wafers, and the gold electrodes are patterned by lithography 
and thermal evaporation. Next, the nanogapped graphene electrode arrays are constructed by 
electron beam lithography (EBL), followed by oxygen plasma etching to functionalize the 
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graphene point contacts with carboxylic acid groups. Lastly, the target molecule is coupled onto 
the carboxylic acid groups on the graphene point contacts via amide bonds to form a GMG-SMJ, 
where the successful formation of a GMG-SMJ is confirmed by a typical I-V curve. The GMG-
SMJ nanodevice is characterized using electrical detection, which transduces molecular 
information into quantized changes in conductance.134-135 This label-free technique is ideal for 
investigating the structural dynamic behavior of a photoswitchable peptide, whereas the 
alternative optical and mechanical detection methods can themselves induce undesirable 
structural changes within the molecule.136-137 Real-time conductance measurements on the 
GMG-SMJ platform enable the structural dynamic behavior of both well-defined cis and 
intrinsically disordered trans peptides to be revealed and compared from within the one single-
peptide, thus elucidating important fundamental insights into this dynamic phenomenon.  
 
Figure 1.10. Schematic representation of a single-molecule junction containing a molecule bridged 
between a pair of nanogapped graphene electrodes, anchored via amide bonds. 
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Figure 1.11. Schematic representations of experimental techniques used to fabricate and study single-
molecule junctions. (a) Mechanically controllable break junctions (MCBJs).118 (b) Atomic force 
microscopy (AFM).122 (c) Electromigration.124 (d) Scanning tunneling microscopy break junctions 
(STM-BJ).121 (e) Oxidative lithography.138   
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Figure 1.12. Experimental setup and real-time conductance measurements of a single-molecule junction 
developed by the Guo group.139 (a) Schematic illustration of the experimental setup of a graphene-
molecule-graphene single-molecule junction (GMG-SMJ) characterized by electrical conductance. (b) 
Real-time conductance measurements to elucidate the dynamic behavior of the single-molecule. The 
right-hand panel shows the corresponding histogram of conductance levels, exhibiting a bimodal 
distribution. Vbias = 300 mV.   
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1.3 Work presented in this thesis 
1.3.1 Photoswitchable antibacterial peptides 
Photopharmacology has been used to modulate the antibacterial activity of cyclic gramicidin S 
peptide mimetics. An azobenzene photoswitch is incorporated into the backbone of gramicidin 
S to allow control of the peptide secondary structure upon photoisomerization. The two corner 
amino acid residues, D-phenylalanine and proline, were chosen for replacement as cis 
azobenzene mimics the β-turn in a cyclic peptide to give a well-defined β-sheet secondary 
structure. In contrast, the trans azobenzene moiety separates both β-strands to totally disrupt the 
secondary structure, resulting in an ill-defined, random configuration. Hence, the cis isomer of 
each peptide mimetic is expected to retain the antibacterial activity of the natural gramicidin S, 
while the trans isomer is not. Moreover, the effects of the positive charges and amphiphilicity 
of the peptide mimetics were also investigated, by substituting the ornithine residues of 
gramicidin S with either arginine (positively charged) or glutamic acid (negatively charged). In 
this thesis, a series of gramicidin S peptide mimetics were rationally designed and synthesized 
to demonstrate the relationship between secondary structure/charge/amphiphilicity and 
antibacterial activity. The peptides are assayed against Staphylococcus aureus (S. aureus) to 
assess their respective antibacterial properties. This study is described in detail in Chapter 2.  
In addition to the aforementioned gramicidin S peptide mimetics, this photopharmacological 
approach was used to modulate the antibacterial activity of three tetrapeptides, based on a known 
synthetic peptide that possesses a rapid bactericidal activity against methicillin-resistant S. 
aureus (MRSA).140 Similarly, an azobenzene photoswitch is integrated into either the N-
terminal side chain, C-terminal side chain, or the C-terminus, to allow reversible switching 
between the cis-enriched and trans-enriched photostationary states (PSS). This study reveals the 
importance of numerous factors influencing antibacterial peptide activity against S. aureus such 
as net positive charge, hydrophobicity, position of the azobenzene photoswitch, secondary 
structure, and amphiphilicity. The study is detailed in Chapter 3.  
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1.3.2 Hypoxia-activated antibacterial prodrug 
A hypoxia-activated prodrug approach offers a possible alternative to photopharmacology to 
control the activity of antibacterial drugs for localized treatment. In this thesis, a hypoxia-
activated antibacterial prodrug based on a broad spectrum antibacterial compound,141 was 
designed and synthesized to contain a protecting group able to be activated under conditions 
that mimic hypoxia, to target both Gram-positive bacteria, S. aureus, and Gram-negative 
bacteria, E. coli. Significantly, the active antibacterial compound is known to be nontoxic 
towards mammalian cells,141 and possesses a lysine residue with free amines at both the N-
terminus and side chain that are essential for its bioactivity. These amines were masked with 4-
nitrobenzylocarbonyl protecting groups to neutralize the cationic charges of the compound, 
thereby abolishing electrostatic interactions that allow binding to the bacteria. Subsequent 
removal of the protecting groups under reductive conditions that mimic hypoxia is proposed to 
restore the binding interaction and hence, antibacterial activity. The full details of this study are 
reported in Chapter 4.  
1.3.3 Unravelling the structural dynamic properties within a 
photoswitchable peptide 
Due to the intrinsic complexity of proteins, model peptides present as ideal alternatives to 
unravel inherent structural dynamic properties.109 Peptide 2a (Figure 2.1, Chapter 2) was chosen 
here as it contains an in-built azobenzene photoswitch to allow reversible interconversion 
between two isomers. We have previously demonstrated that photoisomerization of this peptide 
induces a significant geometric change between a well-defined β-strand geometry of the cis 
isomer and a random, disordered structure for the trans isomer.81 By having both isomers within 
the one simple model, it is possible to study their respective structural dynamic behavior in a 
controlled setting at the most fundamental level. To fabricate this nanodevice, cyclic peptide 2a 
was covalently attached to nanogapped graphene electrodes to form a graphene-molecule-
graphene single-molecule junction (GMG-SMJ), characterized by electrical detection. When 
the peptide is tethered between the nanogapped electrodes, photoisomerization of the 
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azobenzene photoswitch is expected to result in a significant difference in electrical conductance 
between the two isomers due to their distinctive structures. Real-time conductance 
measurements on the GMG-SMJ platform reveal fundamental structural dynamic behavior of 
both well-defined and intrinsically disordered peptides, thus elucidating important insights into 
this dynamic phenomenon which may potentially extend to proteins. This study is presented in 
Chapter 5. 
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Foreword 
Gramicidin S is a natural antibacterial peptide that is particularly active against Gram-positive 
Staphylococcus aureus (S. aureus), but exhibits toxicity towards human erythrocytes. This 
chapter presents a photopharmacological approach to regulate a series of cyclic peptides 1-3 
based on gramicidin S, using an azobenzene photoswitch to reversibly control secondary 
structure and, hence, antibacterial activity. Detailed 1H NMR spectroscopy and density 
functional theory (DFT) calculations were performed to fully characterize the cis-enriched and 
trans-enriched photostationary states (PSS) for each peptide. Each PSS for peptides 1-3 was 
assayed against S. aureus to reveal a clear relationship between secondary structure, 
amphiphilicity, and optimal antibacterial activity. 
 
Figure 2.0. Graphical representation of the model of gramicidin S mimetic, peptide 2b, showing a four-
fold difference in the minimum inhibitory concentration (MIC) between the cis-enriched and trans-
enriched PSS against S. aureus. This photopharmacological approach provides an opportunity to turn 
antibacterial activity ‘on’ and ‘off’ to allow potential future point-of-care applications.  
38 | P a g e  
  
Statement of Authorship 
 
39 | P a g e  
  
 
40 | P a g e  
  
Photopharmacological control of cyclic 
antibacterial peptides 
Yuan Qi Yeoha, Jingxian Yua, Steven W. Polyakb,1, John R. Horsleya and Andrew D. Abella* 
aARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Department of Chemistry, The 
University of Adelaide, SA 5005, Australia. 
bSchool of Biological Sciences, Department of Molecular and Cellular Biology, The University 
of Adelaide, SA 5005, Australia. 
1Present address: School of Pharmacy and Medical Sciences, University of South Australia, 
City East Campus (P4-10), North Terrace, Adelaide, SA 5000, Australia. 
Publication 
Yeoh, Y. Q.; Yu, J.; Polyak, S. W.; Horsley, J. R.; Abell, A. D., Photopharmacological Control 
of Cyclic Antimicrobial Peptides. ChemBioChem 2018, 19 (24), 2591–2597. 
  
41 | P a g e  
  
2.1 Abstract 
Gramicidin S is a naturally occurring antibacterial cyclic peptide. Herein, we present a series of 
cyclic peptides based on gramicidin S that contain an azobenzene photoswitch to reversibly 
control secondary structure and, hence, antibacterial activity. Detailed 1H NMR spectroscopy 
and density functional theory (DFT) calculations revealed a β-sheet/β-turn secondary structure 
for the cis configuration of each peptide, and an ill-defined conformation for all associated trans 
structures. The cis-enriched and trans-enriched photostationary states (PSS) for peptides 1–3 
were assayed against Staphylococcus aureus (S. aureus) to reveal a clear relationship between 
well-defined secondary structure, amphiphilicity, and optimal antibacterial activity. Specifically, 
our results suggest that a synergy exists between these factors, with amphiphilicity playing a 
more significant role than secondary structure in this context. Most notably, peptides 2a and 2b 
exhibited a fourfold difference in antibacterial activity in the cis-enriched PSS over the trans-
enriched equivalent. This photopharmacological approach allows antibacterial activity to be 
regulated through photochemical control of the azobenzene photoswitch, thereby opening new 
avenues in the design and synthesis of future antibiotics.  
42 | P a g e  
  
2.2 Introduction 
Gramicidin S (Figure 2.1) is a naturally occurring cyclic peptide-based antibiotic with a 
symmetrical antiparallel β-sheet conformation, linked by two type-II’ β-turns.1-2 The 
antibacterial properties of gramicidin S have been attributed to its well-defined β-sheet 
secondary structure and overall amphiphilic character.3-8 The peptide contains two basic 
ornithine amino acids and a series of hydrophobic amino acids that allow gramicidin S to bind 
to and penetrate anionic bacterial lipid membranes.9  Gramicidin S is particularly active against 
Gram-positive S. aureus,10-12 thus making it a potentially potent antibiotic to treat a range of 
specific bacterial infections. Photopharmacology presents as an ideal approach to regulate the 
activity of gramicidin S to allow further exploitation of its desirable antibacterial properties. 
Specifically, the introduction of a photoswitch into its backbone allows reversible control of the 
secondary structure and, hence, binding affinity, aggregation, and folding properties.13 
Antibacterial activity can then be switched ‘on’ or ‘off’ upon irradiation with light of a specific 
wavelength, with spatiotemporal precision. This would enhance selectivity and likely reduce 
toxicity and potential for the development of antibacterial resistance.14 Previous studies have 
illustrated the role of a photoswitch in such a photopharmacological approach to modulate the 
activity of membrane channels,15-16 enzyme inhibitors,17-22 anticancer drugs,23-24 and other 
antibiotics.25-26 A recent study incorporated a diarylethene photoswitch into the backbone of 
gramicidin S to regulate antibacterial activity.27 While good antibacterial activity was observed, 
their gramicidin S analogues contain no discernible secondary structure. The difference in 
antibacterial activity between the open and closed forms of their gramicidin S analogues was 
directly attributed to the change in amphiphilicity. Any fundamental relationship between 
secondary structure and amphiphilicity remains to be fully addressed. 
Accordingly, a series of photoswitchable antibacterial peptides (1-3, Figure 2.1) based upon 
gramicidin S was synthesized for an extended study, each containing a meta-/para-substituted 
azobenzene photoswitch incorporated into its backbone. These peptides were chosen to define 
the role of secondary structure and amphiphilicity on antibacterial activity, with both cis-
enriched and trans-enriched PSS assayed against S. aureus. An azobenzene was chosen for 
incorporation into the peptide backbone of gramicidin S as it is known to give rise to a 
significant geometric change, high photoisomerization yield and fast isomerization, while 
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having a relative ease of synthesis.28-32 In addition, an azobenzene in its cis conformation is 
known to mimic the β-turn in β-hairpin structures.33 We anticipated that a suitable azobenzene 
in its cis conformation would mimic the β-turn of the native gramicidin S, allowing the peptide 
to adopt a β-sheet structure. This gramicidin S mimetic would be expected to be active in 
suppressing bacterial growth, whereas the corresponding trans isomer with its ill-defined 
random structure, would not. 
 
Figure 2.1. Chemical structures of gramicidin S and its mimetics, peptides 1-3 (cis isomers). The 
azobenzene photoswitch is highlighted in red in peptides 1-3.  
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2.3 Results and Discussion 
2.3.1 Design and Synthesis of Peptides 1-3 
Cyclic peptides 1-3 (Figure 2.1) mimic the structure and conformation of natural gramicidin S, 
which has the amino acid sequence, cyclo(ᴰFPVOL)2 (ᴰF=D-phenylalanine, O=ornithine). 
Peptide 1 has a similar amino acid sequence to gramicidin S, with proline and D-phenylalanine 
residues replaced by the azobenzene photoswitch. Proline and D-phenylalanine were positioned 
in the β-turn region of the native gramicidin S, where these residues are known to generate a 
well-defined turn in a cyclic structure.27, 34 A meta-/para-substituted azobenzene photoswitch 
(red highlighted region in peptides 1-3, Figure 2.1) was chosen because of its propensity to 
mimic the desired β-turn as defined by modelling results (see 2.3.3 Molecular Modelling). The 
remaining amino acid residues native to gramicidin S were retained in peptide 1, to maintain the 
amphiphilic side chain pattern required for biological activity.6 It was anticipated that, by 
mimicking the β-turn found in the native gramicidin S, the cis isomer of the azobenzene 
photoswitch would bring both β-strands into close proximity to preserve the well-defined 
secondary structure of the peptide. Thus, cis-peptide 1 was expected to retain antibacterial 
activity. Conversely, the azobenzene photoswitch in its trans configuration would be expected 
to disrupt the β-sheet/β-turn character of peptide 1 and, hence, result in diminished activity. 
Modelling of cis-peptide 1 (Figure 2.3) by DFT calculations revealed a distortion in its β-strand 
secondary structure due to strain exerted by the photoswitch on the peptide backbone. The 
leucine residue was removed from the underside strand of 1 to give peptide 2a in order to further 
explore this supposition. Ensuing computational data on 2a was consistent with a more well-
defined β-strand secondary structure. Alternative basic amino acid residues (arginine) and acidic 
amino acid residues (glutamic acid) were incorporated into the structure to investigate the effect 
of positive and negative charges on antibacterial activity, as in peptides 2b and 2c respectively. 
Hence, any observed differences in antibacterial activity would then be directly attributable to 
the positively or negatively charged amino acid residues, as the active cis isomers of 2a-2c 
would be expected to adopt similar secondary structures. The role of amphiphilicity on 
antibacterial activity was investigated by incorporating additional basic amino acid residues into 
the peptide backbone (3a and 3b) in place of the hydrophobic amino acids leucine and valine. 
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All peptides and a gramicidin S control were synthesized by solid phase peptide synthesis 
(SPPS) as outlined in the Experimental section, and crude products were purified by RP-HPLC 
prior to biological testing. The component azobenzene photoswitch was synthesized using an 
existing methodology.35 
2.3.2 Spectroscopic Analysis for Peptides 1-3 
For all experiments, the thermally stable trans-enriched PSS was isomerized to a cis-enriched 
PSS by irradiation using UV light (352 nm). Conversely, cis to trans isomerism was induced by 
irradiation with visible light (405 nm). The trans-enriched PSS of each peptide (1-3) exhibited 
a broad absorption band (λmax = 328-330 nm), whereas each cis-enriched PSS displayed a 
stronger absorbance at 428 nm, and an absorbance of much lower intensity at 328-330 nm 
(Figure S2.1). These observed values concur with literature.36 The intense absorbance at 328-
330 nm is due to the symmetry allowed π → π* transition, while the weak absorbance peak at 
428 nm is the result of the symmetry forbidden n → π* transition.37 A far less intense absorption 
band at 328 nm was apparent for the cis-enriched PSS of peptides 1-3, which is likely due to a 
small amount of trans isomer remaining after irradiation. Both azobenzene isomers are known 
to give some overlap of absorption spectra.38 
A more quantitative measure of each PSS was determined by the ratio of ¹H NMR integrals. 
Figures S2.4a and S2.5a (boxed areas) show the ratios between the cis and trans PSSs, 
calculated from the 1H NMR integrals at δ = 7.91and 6.83 for peptide 1 and δ = 7.83 and 6.81 
for peptide 2a. These ¹H NMR resonances correspond to hydrogens of the para-substituted 
phenyl ring in the trans and cis isomers of the azobenzene unit respectively.39 It was determined 
that the photoisomerization yield for the cis-enriched PSS of peptides 1-3 was relatively high, 
ranging from 64%-90%, as detailed in Table 2.1. The secondary structures of the peptides 1-3 
were defined by ¹H NMR, with 3JNHCαH coupling constants in the range of 8-10 Hz
40 for a β-
strand. Analysis of the cis-enriched PSS of 2a-2c revealed 3JNHCαH coupling constants of 8.0-
8.8 Hz, consistent with a more well-defined β-strand structure than the cis isomers of 1 and 3. 
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The half-lives for the cis-enriched PSS of each peptide (Table 2.1) were determined to be 
between 2-4 days, by analyzing the kinetics of the cis-trans thermal back isomerization. 
However, the cis-enriched PSS of peptides 2a-2c have longer half-lives than the cis-enriched 
PSS of peptides 1 and 3, which have less well-defined secondary structures as revealed by ¹H 
NMR. The half-lives for the cis-enriched PSS of peptides 2a-2c range between 3.5-4 days, thus 
highlighting their robustness and stability. This considerable time frame is sufficient for 
antibacterial assaying against S. aureus, which in this case was 16-20 hours. 
Table 2.1. Photoisomerization yields and half-lives of gramicidin S mimetics, peptides 1-3, in their 
respective photostationary states (PSS). 
Peptide 
Photoisomerization Yield (%) 
Half-Life (cis-enriched PSS) (h) 
cis trans 
1 90 84 74.8 
2a 90 88 84.2 
2b 71 75 99.9 
2c 90 85 97.0 
3a 84 66 87.8 
3b 64 67 48.4 
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2.3.3 Molecular Modelling for Peptides 1-3 
The lowest energy structure for the cis isomer of peptide 1 (Figure 2.3) was determined by 
density functional theory (DFT). The resulting model revealed four intramolecular hydrogen 
bonds linking the upper and lower strands, with two of these considered strong bonds (2.0 Å 
and 2.2 Å), and the other two moderate to weak (2.5 Å and 3.8 Å). The cis isomers of peptides 
2 and 3 contain three strong hydrogen bonds (1.8 Å-2.0 Å, Table S2.2). In comparison, native 
gramicidin S possesses four strong intramolecular hydrogen bonds (2.0 Å-2.3 Å) (Figure 2.2a) 
connecting the upper and lower strands of the cyclic peptide, which play an important role in 
defining its β-sheet structure. The trans isomers for each of peptides 1-3 lack intramolecular 
hydrogen bonding and, hence, secondary structure. The computational molecular models for 





Figure 2.2. Molecular models of gramicidin S. (a) Containing four strong intramolecular hydrogen 
bonds, highlighted in yellow. (b) Containing two β-turns, indicated by the distances between Cα(i) and 
Cα(i+3) = 5.0 Å (< 7 Å), highlighted in yellow.  
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The calculated backbone dihedral angles for the trans isomers of peptides 1-3 were found to be 
outside the allowable ϕ, ψ, and ω angles specific to a β-strand structure.41 A standard β-sheet 
should contain more than 30% β-sheet content.42 The cis isomers of peptides 2a-2c were found 
to contain 43% β-sheet content, while the cis isomers of peptides 1 and 3 contain 29%. Notably, 
the cis isomer of 1 showed a large kink on the underside of the backbone, which distorts the β-
sheet structure of the peptide (Figure 2.3). A β-turn is denoted by four consecutive ‘corner’ 
amino acid residues i to i+3,34  and is considered to be present if two specific criteria are fulfilled: 
i) a distance of less than 7 Å between the Cα(i) and Cα(i+3), and ii) the (i+1) and (i+2) residues 
are not in an α-helix.43 Based on these parameters, gramicidin S possesses two β-turns (Figure 
2.2b) in agreement with previous reports,1-2 with Cα(i) to Cα(i+3) distance of 5.0 Å. The cis 
isomer of peptides 1-3 contains a β-turn, with Cα(i) to Cα(i+3) distances ranging between 5.7 Å 
and 6.0 Å. The corresponding distance for each of the trans isomers of 1-3 exceeds 7 Å, 
indicating the random nature in each case. Figure 2.4b shows the molecular models for peptide 
2b, highlighting the presence of a β-turn in the cis isomer, whereas the trans isomer is devoid 
of a β-turn. 
 
Figure 2.3. Molecular model for the cis isomer of peptide 1, showing the presence of four intramolecular 
hydrogen bonds linking the upper and lower strands, with two of these considered strong bonds (2.0 Å 
and 2.2 Å), and the other two moderate to weak (2.5 Å and 3.8 Å). A large kink is evident on the 
underside strand of the backbone, which distorts the β-sheet structure of the peptide. 
  






Figure 2.4. Molecular models of peptide 2b. (a) The cis isomer (left) contains three strong 
intramolecular hydrogen bonds, highlighted in yellow, but no intramolecular hydrogen bond is evident 
for the trans isomer (right). (b) The cis isomer of peptide 2b possesses a β-turn, indicated by the distance 
between Cα(i) and Cα(i+3) = 5.70 Å (< 7 Å), but the trans isomer is devoid of a β-turn, as the distance 
between Cα(i) and Cα(i+3) = 8.00 Å (> 7 Å).  
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2.3.4 Biological Assay for Peptides 1-3 
Peptides 1-3 and gramicidin S were assayed for their antibacterial activity against S. aureus 
ATCC 49775, as detailed in the Experimental section. Briefly, each peptide was dissolved in 
DMSO at a concentration of 8 mg/mL, and irradiated separately using either UV (352 nm) or 
Vis (405 nm) light for 2h to obtain the respective cis-enriched and trans-enriched PSS. Two-
fold serial dilutions were made for each peptide, which were then separately inoculated with S. 
aureus at 37°C for 16-20 hours. The lowest concentration that inhibited bacterial growth was 
reported as the minimal inhibitory concentration (MIC). The minimum inhibitory concentration 
(MIC) of the prototypical peptide gramicidin S was in agreement with previous reports27, 44 (2 
μg/mL, Table 2.2). No detectable difference in bioactivity was observed between the cis-
enriched and trans-enriched PSS of 1 (MIC 64 μg/mL). This result is consistent with the earlier 
molecular modelling study (see 2.3.3 Molecular Modelling) which showed a distorted β-strand 
secondary structure in peptide 1 due to the photoswitch. Peptides 2a and 2b, both designed to 
address the strain on the peptide backbone, showed differential bioactivity due to 
photoswitching. For 2a, the cis-enriched PSS was fourfold more active than the trans-enriched 
equivalent (Table 2.2). This important finding demonstrates that the antibacterial activity of the 
peptide can be regulated by controlling the peptide secondary structure through 
photoisomerization. Consistent with this observation, the cis-enriched PSS of 2b also afforded 
fourfold greater bioactivity over its trans-enriched equivalent. Indeed, cis-enriched 2b provided 
the most potent antibacterial analogue in this series (MIC 32 μg/mL). These findings are 
consistent with our design principles where substitution of ornithine residues with arginine 
residues, as in peptide 2b, was predicted to enhance membrane penetrating properties,45 
resulting in improved antibacterial activity. In further agreement, both PSS of the glutamic acid-
containing peptide 2c were inactive against S. aureus at the highest concentration tested (256 
μg/mL), confirming the importance of basic amino acids for antibacterial activity. Replacement 
of hydrophobic residues valine and leucine with arginine residues (3a and 3b) resulted in a 
decrease in antibacterial activity, presumably due to disruption of the amphiphilic nature of the 
peptides with associated decreased penetration through the bacterial membrane. As 3a and 3b 
both possess approximately 30% β-sheet character, we postulate that amphiphilicity plays a 
more significant role than secondary structure in this context. Together, our experimental and 
computational data shows that antibacterial activity in these gramicidin S peptide mimetics is 
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dependent on a fine balance between well-defined secondary structure and the amphiphilic 
nature of the amino acid side chains. Indeed, our gramicidin S analogues have indicated a 
synergy between these two factors, where the well-defined β-sheet framework is likely essential 
for stabilizing the residues responsible for maintaining amphiphilicity. 
Table 2.2. Minimum inhibitory concentration (MIC) of gramicidin S and its mimetics, peptides 1-3, in 
their respective photostationary states (PSS). 
Peptide PSS MIC (µg/mL) 
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2.4 Conclusion 
In this study, a series of photoswitchable cyclic peptides (1-3) based on the antibacterial agent 
gramicidin S was synthesized, each containing an azobenzene moiety for reversible switching 
between a trans isomer possessing an ill-defined conformation, and a cis isomer containing a 
well-defined secondary structure. Each peptide was assayed against S. aureus, with 
photoisomerization from trans-enriched to cis-enriched PSS resulting in significant differences 
in biological activity. Specifically, peptides 2a and 2b showed a fourfold difference in the 
minimum inhibitory concentration (MIC) values against S. aureus, between their respective cis-
enriched and trans-enriched PSS, with the well-defined cis-enriched PSS found to be more 
active. These results confirmed that the secondary structure of the peptide and, hence, 
antibacterial activity can be regulated through photochemical control of the azobenzene 
photoswitch. Replacement of the hydrophobic valine and leucine residues with basic arginine 
residues gave peptides 3a and 3b, which were devoid of activity. Collectively, these results 
show that both well-defined secondary structure and amphiphilicity are essential for 
antibacterial activity against S. aureus. Furthermore, our findings suggest it is possible that 
amphiphilicity is more important for membrane penetration, where no conformational 
molecular recognition is required, unlike for most protein-protein interactions, for example, 
where well-defined secondary structure is crucial. This photopharmacological approach may 
offer benefits for the design of future antibiotics that possess significant therapeutic value, but 
are limited by factors such as bioavailability. This important strategy provides an opportunity 
to turn antibacterial activity ‘on’ and ‘off’ to allow potential future point-of-care applications. 
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2.7 Supplementary Information  
2.7.1 Materials 
Fmoc-D-Phe-OH, hydroxybenzotriazole (HOBt) and N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC.HCl) were purchased from GL Biochem (Shanghai) 
Ltd., China. Dichloromethane (CH2Cl2), N,N‐dimethylformamide (DMF), piperidine and 
methanol (MeOH) were purchased from Merck, Australia. 4-aminobenzylamine, 3-
aminobenzoic acid, Fmoc-Glu(tBu)-OH, trifluoroacetic acid (TFA), acetonitrile and 
diisopropylethylamine (DIPEA) were purchased from Sigma–Aldrich, Australia. Toluene, 
dimethylsulfoxide (DMSO), and acetic acid were purchased from Chem Supply, Australia. 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid (HATU), 2-
Chlorotrityl chloride resin, Fmoc-L-Pro-OH, Fmoc-L-Orn(Boc)-OH, Fmoc-L-Leu-OH, Fmoc-
L-Val-OH, and Fmoc-Arg(Pbf)-OH were purchased from Chem-Impex International, Inc., USA. 
All solvents and reagents were used without purification unless noted. 
2.7.2 Methods 
2.7.2.1 High Performance Liquid Chromatography (HPLC) 
The synthetic cyclic peptides 1-3 were analyzed and purified by reverse phase high performance 
liquid chromatography (RP-HPLC), using a Gilson purification system equipped with a UV-Vis 
absorbance detector and a Supelco Analytical C18 column (Discovery BIO Wide Pore C5-5, 250 
x 10 mm, 5 μm). Aqueous solvent A: Water:TFA (100:0.1 v/v) and organic solvent B: 
ACN:TFA (100:0.08 v/v) were used during the purification process.   
59 | P a g e  
  
2.7.2.2 Mass Spectrometry 
High resolution mass spectral data were obtained using an Agilent 6230 TOF LC/MS mass 
spectrometer. Mass spectra were obtained over a range of 100 < m/z < 2000.  
2.7.2.3 UV-Vis Spectrophotometry 
All UV-Vis spectra were obtained at 30 ± 0.5°C on the Varian Cary 5000 UV-Vis 
spectrophotometer. All measurements were performed using quartz cuvettes with a 
concentration of approximately 100 μg/mL of 1-3 in DMSO. For conversion from a trans to a 
cis conformation, 1-3 were irradiated for 2 hours, under a UV lamp (UVP® MRL-58, 352 nm) 
prior to each measurement. For conversion from the cis to trans isomer, visible light (405 nm) 
was used. The absorbances for the respective conformations of 1-3 were measured between 200-
800 nm. 
2.7.2.4 NMR Spectroscopy 
¹H NMR spectrum of the azobenzene photoswitch was recorded in DMSO-d6 solution using an 
Agilent DD2 500MHz spectrometer. ¹H NMR spectra of the cyclic peptides were recorded on 
an Agilent DD2 600MHz NMR spectrometer. Chemical shifts are reported in ppm (δ) using 
TMS (0.00 ppm) as the internal standard. Signals are recorded as s (singlet), d (doublet), t (triplet) 
or m (multiplet). 
2.7.2.5 Molecular Modelling 
The lowest energy structures for cis and trans isomers of peptides 1-3 and a natural gramicidin 
S were determined in collaboration using Gaussian 091 package on the National Computing 
Infrastructure (NCI) National Facility, e.g. Raijin supercomputer. The initial geometries of 
peptides 1-3 and gramicidin S were constructed through GaussView 5.0 program. The geometry 
of each structure was optimized in the gas phase using the density functional theory (DFT) with 
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the B3LYP density function and basis sets of increasing size from STO-3G up to 6-31G** for 
all atoms. 
2.7.3 Experimental 
2.7.3.1 Synthesis of Azobenzene Photoswitch 
3-nitrosobenzoic acid 
 
To a solution of 3-aminobenzoic acid (5.0 g, 36.5 mmol) in dichloromethane (100 mL), a 
solution of oxone (22.4 g, 73.0 mmol) in water (400 mL) was added dropwise, and the mixture 
was stirred vigorously for 4h at rt. The mixture was filtered and dried overnight under vacuum 
to yield a yellow solid (5.0 g, 90%). 1H NMR (500 MHz, DMSO-d6): δ 8.41-8.39 (m, 1H), 8.36-
8.35 (m, 1H), 8.20-8.17 (m, 1H), 7.89 (t, J = 7.8 Hz, 1H). 
(9H-fluoren-9-yl) methyl 4-aminobenzylcarbamate 
 
To a mixture of 4-aminobenzylamine (2.0 g, 16.4 mmol) in water (32 mL) and tetrahydrofuran 
(12 mL), 5% NaHCO3 (1.5 mL) was added, and the mixture was stirred for 10 min at rt. N-(9-
fluorenylmethoxycarbonyloxy)succinimide (5.5 g, 16.4 mmol) was suspended in 
tetrahydrofuran (20 mL) and the suspension was added dropwise, and the mixture stirred for 
24h at rt. Water (500 mL) was added to the mixture and the product was precipitated as a pale 
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yellow solid. The precipitate was filtered and dried in vacuo to give a yellow solid (4.8 g, 84%). 
1H NMR (500 MHz, DMSO-d6): δ 7.88 (d, J = 7.5 Hz, 1H), 7.69 (d, J = 7.5 Hz, 1H), 7.63 (t, J 
= 6.0 Hz, 1H), 7.41 (t, J = 7.3 Hz, 1H), 7.32 (t, J = 7.5 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 6.49 
(d, J = 8.3 Hz, 1H), 4.30 (d, J = 7.0 Hz, 1H), 4.21 (d, J = 6.7 Hz, 1H), 3.99 (d, J = 6.0 Hz, 1H). 
Azobenzene Photoswitch 
 
To a solution of 3-nitrosobenzoic acid (2.3 g, 15.4 mmol) in DMSO (50 mL), glacial acetic acid 
(50 mL) was added, and the mixture was stirred for 10 min at rt. (9H-fluoren-9-yl) methyl 4-
aminobenzylcarbamate (2.6 g, 7.7 mmol) was added to the reaction mixture and stirred 
overnight under N2 at rt. The mixture was filtered under suction to reveal an orange solid. The 
remaining product in the filtrate was extracted by CH2Cl2 (50 mL), and the mixture was washed 
with water (2 x 50 mL) to remove acetic acid/DMSO. The organic layer was removed under N2 
to obtain an orange solid. The two orange solids were combined and dried in vacuo. The crude 
product was purified by column chromatography (9:1 CH2Cl2/methanol) to give an orange solid 
(2.3 g, 63%). R.f (9:1 CH2Cl2/methanol) = 0.4. 
1H NMR (500 MHz, DMSO-d6): δ 13.30 (s, 1H), 
8.38 (s, 1H), 8.16-8.11 (m, 2H), 7.95 (t, J = 6.1 Hz, 1H), 7.90 (d, J = 6.9 Hz, 4H), 7.76-7.71 (m, 
3H), 7.45-7.40 (m, 4H), 7.34 (t, J = 7.4 Hz, 2H), 4.40 (d, J = 6.7 Hz, 2H), 4.29 (d, J = 6.0 Hz, 
2H), 4.25 (t, J = 6.5 Hz, 1H). HRMS: (m/z) calc for C29H23N3O4: 478.1722 [M+H]
+, found: 
478.1759.  
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2.7.3.2 Solid Phase Peptide Synthesis (SPPS) of Linear Peptides 
Standard Fmoc-based SPPS and commercially available reagents were used for the synthesis of 
the linear peptides. 2-Chlorotrityl chloride resin preloaded with Fmoc-D-Phe-OH (0.58 mmol/g, 
1.0 g, 1 equiv.) was used to synthesize the linear precursors. The unreacted active sites on the 
resin were capped with 17:2:1 CH2Cl2/MeOH/DIPEA (2 x 25 mL) for 30 min before washing 
the resin with CH2Cl2 (x3), DMF (x3) and CH2Cl2 (x3). N-Fmoc deprotection was carried out 
by treating the resin with 25% piperidine/DMF (25 mL) for 30 min before washing with CH2Cl2 
(x3), DMF (x3) followed by CH2Cl2 (x3). Couplings of the amino acids and azobenzene 
photoswitch were performed using the following molar ratios of reagents: Fmoc-amino acids 
and Fmoc-azobenzene photoswitch (2 equiv.) dissolved in DMF (20 mL), 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU)/DMF (0.5 M, 2 equiv.) and DIPEA (8 equiv.). The resin was 
washed with CH2Cl2 (x3), DMF (x3) followed by CH2Cl2 (x3), and the coupling procedures 
were repeated. The coupling time in all cases was 2h. Deprotection and coupling procedures 
were repeated alternatively until the sequence was completed. After the peptide sequences were 
completed and deprotected, the resin was washed with CH2Cl2 (x3), DMF (x3) followed by 
CH2Cl2 (x3) and dried under vacuum. The linear precursors were cleaved from the resin using 
1.5% TFA in CH2Cl2 (2 x 20 mL) while maintaining the side chain protection of 
ornithine/arginine/glutamic acid residues. The reagents were left to stand for 15 min with 
stirring before filtering the peptide solution. The volatile products from the filtrate were 
removed by N2 flow, and the linear peptides were placed under vacuum for 4h, to yield a crude 
orange solid. 
2.7.3.3 Cyclization of Linear Peptides  
Respective solutions of crude linear peptides in methanol (22 mg/mL) were irradiated by UV 
light (λ = 352 nm) for 4h, to convert the azobenzene into its cis isomer prior to cyclization. The 
solvent was removed in vacuo, and the residue was placed under vacuum for 30 min. The linear 
peptides were each dissolved in dry DMF (0.03 mmol/mL) and cyclized using the following 
reagents: HOBt (5 equiv.), EDC.HCl (5 equiv.) and DIPEA (10 equiv.) in dry DMF (63 mL). 
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The mixture was kept away from visible light using an aluminium foil cover and stirred 
overnight under N2 conditions at rt. DMF was then removed by N2 flow. The crude cyclic 
peptides were washed with toluene (3 x 20 mL) and methanol (3 x 30 mL) to remove residual 
DMF, and the solvent was removed in vacuo. The cyclic peptides were then dissolved in CH2Cl2 
(60 mL), and the solutions were washed with saturated NaHCO3 (4 x 60 mL) and brine (2 x 60 
mL). The organic layer was dried over MgSO4, and the solvent was removed in vacuo. The 
residue was dried under vacuum for 4h to yield an orange solid. 
2.7.3.4 Deprotection of Side Chain Protecting Groups 
The Boc protecting groups on the side chains of all ornithine residues were removed by 
treatment with 50% TFA/CH2Cl2 (v/v, 10 mL) for 1h. The volatiles were removed by a stream 
of N2 to give gramicidin S and peptides 1 and 2a, as orange solids. The Pbf protecting groups 
on the side chains of all arginine residues were removed by treatment with TFA/TIPS/H2O 
(95:2.5:2.5, 10 mL) for 1h. The volatiles were removed by a stream of N2 to give peptides 2b 
and 3a-3b, as orange solids. The tBu protecting groups on the side chains of both glutamic acid 
residues were removed by treatment with TFA/CH2Cl2 (9:1, v/v, 10 mL) for 1h. The volatiles 
were removed by a stream of N2 to give peptide 2c as an orange solid. All crude products were 
purified by RP-HPLC. Fraction collection was set for peak-based collection at 220 nm and 320 
nm for gramicidin S and peptides 1-3 respectively. The identity of the pure products was 
confirmed by mass spectrometry. 
2.7.3.5 Photoisomerization of Peptides 1-3 
Peptides 1-3 were dissolved in DMSO at a concentration of 100 μg/mL and exposed to visible 
light of 405 nm for 2h to yield the trans-enriched PSS. The trans-enriched PSS of 1-3 were 
irradiated by UV light of 352 nm for 2h, to convert to the respective cis-enriched PSS.   
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2.7.3.6 Half-Life Analysis of Peptides 1-3 
The half-life of peptides 1-3 was determined by UV-Vis spectrophotometry.2 Prior to irradiation, 
peptides 1-3 in their thermally stable trans-enriched PSS were dissolved in DMSO, and the 
wavelengths of maximum absorbance (λmax) were measured using a Synergy H4 Hybrid Multi-
Mode Microplate Reader. The peptides were then irradiated under UV light (352 nm) for 2h to 
convert the samples to their cis-enriched PSS, and the λmax were determined. The samples were 
irradiated under UV (352 nm) for a further 30 min to achieve the maximum attainable cis-
enriched PSS, which was confirmed when no further increase was observed in the absorbance. 
Each peptide in its cis-enriched PSS was stored in the dark, to switch the samples back to their 
respective trans-enriched PSS by thermal relaxation. The absorbance for each peptide was 
measured every 10 min to monitor the change in the absorbance at 328 nm, which is 
characteristic of the trans-enriched PSS. The measurements were conducted over a period of 
62h. The absorbance at 328 nm increased gradually over 62h for all peptides, which indicated 
the cis-trans thermal back isomerization. The absorbance curves at 328 nm gradually reached a 
plateau when the peptides reached their maximum attainable trans-enriched PSS. The average 
of the triplicates was calculated to obtain the average half-life for each sample. The half-life for 
each peptide was calculated by analyzing the increase in the UV-Vis absorbance curves2 at 328 
nm, using curve fitting in the GraphPad Prism 7.03 software. 
2.7.3.7 Molecular Modelling 
The lowest energy structures for the cis and trans isomers of peptides 1-3 were determined in 
the gas phase using the NWChem 6.6 package,3 with tight convergence criteria using a hybrid 
B3LYP functional with 6-31G** basis set for all atoms. The initial geometries of peptides 1-3 
were constructed through the GaussView 5.0 package by modifying the corresponding 
gramicidin S unit comprised in the X-ray crystal structure (entry code 2019361, Crystallography 
Open Database http://www.crystallography.net), as reported.4 The azobenzene moiety in either 
cis or trans conformation was incorporated into the cyclic structure, to replace the corner 
residues (proline and D-phenylalanine). Conformational analyses including dihedral angles, 
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overall molecular lengths, and intramolecular hydrogen bond lengths, were conducted using the 
Chimera 1.11 software.5 
2.7.3.8 Biological Assays (Antibacterial Susceptibility Evaluation) 
Antibacterial activity was determined by the microdilution broth method as recommended by 
the CLSI (Clinical and Laboratory Standards Institute, Document M07-A8, 2009, Wayne, PA.) 
using cation-adjusted Mueller-Hinton broth (Trek Diagnostics Systems, U.K.). Serial two-fold 
dilutions of each peptide were made using DMSO as the diluent. Trays were inoculated with 5 
x 104 CFU of S. aureus ATCC 49975 in a volume of 100 μL (final concentration of DMSO was 
3.2% (v/v)) and incubated at 37 °C for 16-20h. Growth of the bacterium was quantified by 
measuring the absorbance at 620 nm.  
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2.7.4 UV-Vis Spectrum for Peptides 1-3  
The UV-Vis spectra for the cis-enriched and trans-enriched PSS of peptides 1-3 were recorded 
in Figure S2.1.  
 
Figure S2.1. UV-Vis spectra for the trans-enriched PSS (blue) and cis-enriched PSS (red) after 2 hours 
of irradiation under visible light (405 nm) and UV light (352 nm) respectively. The trans-enriched PSS 
show a maximum absorbance in the 320 nm region, whereas the cis-enriched PSS have a higher 
absorbance at 428 nm, and an absorbance of much lower intensity at 320 nm.  
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2.7.5 1H NMR Spectroscopy 
The 1H NMR spectrum for the azobenzene photoswitch was recorded in the relaxed trans 
conformation on an Agilent DD2 500 MHz NMR spectrometer, while the 1H NMR spectra for 
the gramicidin S and peptides 1-3 were recorded on an Agilent DD2 600 MHz NMR 
spectrometer. Prior irradiation, peptides 1-3 predominantly in the trans-enriched PSS were 
dissolved in methanol-d6 or DMSO-d6 and the NMR spectra were recorded. Subsequently, the 
trans-enriched PSS were irradiated under UV (352 nm) for the conversion into their 
corresponding cis-enriched PSS and the NMR spectra were again recorded. The 3JNHCα for the 
cis-enriched PSS of peptides 1-3 were determined based on the amide NH shifts. The ratios of 
peak integrations for peptides 1-3 revealed the photoisomerization yield of the cis-enriched and 
trans-enriched PSS of each peptide. The connectivity of the peptides was determined by 2D 
NMR, ie. TOCSY and ROESY. 




NH shifts,  (ppm) 







8.33 (t, J=1.9 Hz, 1H) 
0.23 : 2.15 90 
8.11-8.08 (m, 1H) 
8.02-7.99 (d, 8.3 Hz, 3H) 
7.75 (d, 8.3 Hz, 1H) 
7.69 (t, J=7.8 Hz, 1H) 
trans ND 2.44 : 0.48 84 
2a 
cis 
8.41 (d, J=6.5 Hz, 1H) 
0.23 : 2.17 90 
8.37 (t, J=6.1 Hz, 1H) 
8.27 (t, J=8.1 Hz, 2H) 
7.93 (d, J=8.8 Hz, 1H) 
7.83 (d, J=8.4 Hz, 1H) 
7.64 (d, J=7.6 Hz, 1H) 
trans ND 2.06 : 0.27 88 
2b 
cis 
8.49 (d, J=8.2 Hz, 1H) 
0.96 : 2.37 71 
8.36-8.31 (m, 1H) 
8.24 (d, J=7.8 Hz, 2H) 
7.91 (d, J=8.6 Hz, 2H) 
7.73 (d, J=8.5 Hz, 1H) 
trans ND 2.14 : 0.70 75 




8.26 (t, J=8.0 Hz, 2H) 
0.24 : 2.27 90 
8.12 (d, J=8.2 Hz, 1H) 
8.02 (d, J=7.3 Hz, 2H) 
7.84 (d, J=8.7 Hz, 1H) 
7.67 (d, J=8.5 Hz, 1H) 
trans ND 2.07 : 0.36 85 
3a 
cis 
8.64-8.56 (m, 1H) 
0.40 : 2.15 84 
8.40-8.33 (m, 1H) 
8.31-8.24 (m, 3H) 
8.11 (d, J=5.8 Hz, 1H) 
7.78 (d, J=8.1 Hz, 1H) 
trans ND 2.14 : 1.11 66 
3b 
cis 
8.56 (d, J=6.3 Hz, 1H) 
1.07 : 1.93 64 
8.43 (d, J=8.7 Hz, 1H) 
8.14-8.10 (m, 1H) 
8.05 (d, J=7.9 Hz, 1H) 
7.98-7.88 (m, 2H) 
7.82 (d, J=8.1 Hz, 1H) 
trans ND 2.20 : 1.08 67 
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2.7.5.1 1H NMR Spectra 
 
Figure S2.2a. 1H NMR spectrum of 3-nitrosobenzoic acid. 
 
Figure S2.2b. 1H NMR spectrum of (9H-fluoren-9-yl) methyl 4-aminobenzylcarbamate. 
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Figure S2.2c. 1H NMR spectrum of azobenzene photoswitch. 
 
Figure S2.3. 1H NMR spectrum of gramicidin S. 
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Figure S2.4a. 1H NMR spectrum of cis- (red) and trans-enriched (blue) PSSs of peptide 1. Boxed areas 
at δ 7.91 and δ 6.83 show the ratio between the cis- and trans-enriched PSSs. 
 
Figure S2.4b. COSY spectrum of the cis-enriched PSS of peptide 1. 
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Figure S2.4c. COSY spectrum of the trans-enriched PSS of peptide 1. 
 
Figure S2.5a. 1H NMR spectrum of cis- (red) and trans-enriched (blue) PSSs of peptide 2a. Boxed 
areas at δ 7.83 and δ 6.81 show the ratio between the cis- and trans-enriched PSSs. 
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Figure S2.5b. COSY spectrum of the cis-enriched PSS of peptide 2a. 
 
Figure S2.5c. COSY spectrum of the trans-enriched PSS of peptide 2a.  
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2.7.6 Half-life Analysis  
The absorbance at 328 nm increased gradually over 62h for peptides 1-3, which indicated the 
cis-trans thermal back isomerization.2 The absorbance curves at 328 nm gradually reached a 
plateau when peptides 1-3 were at their maximum attainable trans-enriched PSS. The half-life 
for each peptide was calculated by analyzing the increase in the UV-Vis absorbance curves at 
328 nm, using curve fitting for non-linear regression of one-phase association.  
 
Figure S2.6. The absorbance curves of peptides 1-3 at their respective λmax when left in the dark for 62h. 
The gradual increase in the absorbance at 328 nm indicates the cis-trans thermal back isomerization of 
the peptide samples.  
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2.7.7 Molecular Modelling 
Key structural differences between the cis-enriched and trans-enriched isomers of peptides 1-3 
are summarized in Table S2.2-S2.3. 

















































3 4 5.7 Present 1.9 
1.9 




3 3 5.8 Present 2.0 
1.8 




3 3 5.7 Present 1.9 
1.8 




3 2 5.8 Present 2.0 
1.8 




3 2 5.8 Present 2.0 
1.8 
trans 9 - 0 0 8.4 Absent 
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Dihedral Angles (°) β-Sheet 
Content 
(%) ϕ ψ ω 
Gramicidin S - 
Pro -83.7 -1.9 -179.9 
50 
Val -86.6 139.3 166.2 
Orn -135.2 134.5 173.3 
Leu (i) -136.8 107.3 -174.4 
D-Phe (i + 1) 52 -126.4 -175.3 
Pro (i + 2) -80.3 5.1 -179.6 
Val (i + 3) -108.4 126 169.2 
Orn -112.9 135.4 177.9 
Leu -141.1 103.2 -173.2 
D-Phe 53.5 -128.8 -176.2 
1 
cis 
Val -121 146.9 173.5 
25 
Orn -79.3 156 175.6 
Leu (i) -143.4 -161.6 -177.9 
D-Phe (i + 1) -78.8 -118.3 -174.1 
Pro (i + 2) -61.8 -38 168.6 
Val (i + 3) -81.7 87.6 -159.3 
Orn -71.6 -27.5 171.3 
Leu -117.7 125.7 179.8 
trans 
Val -132.6 146.5 171.9 
13 
Orn -58.2 139.1 -171 
Leu (i) -166.1 157.6 168.2 
D-Phe (i + 1) -70 -163 -160.7 
Pro (i + 2) -84.9 48.7 174.2 
Val (i + 3) -85.4 82.9 -160.2 
Orn -77.6 -13.6 166.6 
Leu 24.9 148.8 -14.7 
  




Val -119.1 132.3 177.9 
43 
Orn -150.6 160.7 166.2 
Leu (i) -120.9 -115.8 172.4 
D-Phe (i + 1) -100.8 109.7 177.8 
Pro (i + 2) 79 -62.1 177.4 
Val (i + 3) -59.4 130.7 -176.3 
Orn -153.1 154.6 176.8 
trans 
Val -134.2 38.1 -169.3 
14 
Orn -82.6 66.4 -173.6 
Leu (i) -74.9 -22.9 -177.7 
D-Phe (i + 1) -155.7 140.9 159.8 
Pro (i + 2) 82.4 -56.2 -167.2 
Val (i + 3) -81.4 73 173.4 
Orn -67.4 146.8 -171.6 
2b 
cis 
Val -110.9 129.7 -179.8 
43 
Arg -159.3 161.6 155.9 
Leu (i) -107.7 -104.5 160.6 
D-Phe (i + 1) -127 147.5 -179.2 
Pro (i + 2) 76.2 -69.8 177.5 
Val (i + 3) -74 123.8 -173.8 
Arg -157.9 150.8 176.9 
trans 
Val -121.5 88.7 -165 
0 
Arg -84.7 62.1 -174.5 
Leu (i) -84 -44.1 -174 
D-Phe (i + 1) -172.3 151 156.4 
Pro (i + 2) 82 -51.7 -165.3 
Val (i + 3) -79.9 73.4 174.8 
Arg -70.8 133.4 -172.2 
2c 
cis 
Val -115 128.8 179.3 
43 
Glu -150.9 162.3 161.3 
Leu (i) -108.2 -110.6 169.1 
D-Phe (i + 1) -108.8 115.1 177.5 
Pro (i + 2) 78.9 -63.6 176.9 
Val (i + 3) -59.3 125.4 -172.1 
Glu -153.9 155 171.5 
trans 
Val -132.2 39.5 -169 
29 
Glu -81.1 60 -170.9 
Leu (i) -89.1 -24 -176.5 
D-Phe (i + 1) -156.9 134 168.4 
Pro (i + 2) 80.4 -67.9 -178.3 
Val (i + 3) -80.4 80 -177.9 
Glu -104.9 129.4 -174.2 





Val -112.8 130.1 179.4 
29 
Arg -153.3 160.5 155.8 
Leu (i) -106.8 -105.3 161 
D-Phe (i + 1) -126.5 146.2 -179 
Pro (i + 2) 75.2 -69.8 178.3 
Arg (i + 3) -74.4 130.2 -172 
Arg -162 152.8 177.4 
trans 
Val -84.5 67.6 -160.2 
0 
Arg -87.2 60.9 -171.5 
Leu (i) -100.5 -27.8 -171.7 
D-Phe (i + 1) -165.7 143.2 152.9 
Pro (i + 2) 79.1 -58.2 -154.9 
Arg (i + 3) -85.3 70 175.4 
Arg -57.3 135.8 -171.2 
3b 
cis 
Val -113 130.1 179.7 
29 
Arg -153.8 161.1 155 
Arg (i) -107.4 -104.3 161.9 
D-Phe (i + 1) -127.5 146.2 -178.9 
Pro (i + 2) 75.1 -70.2 178.4 
Arg (i + 3) -74.9 129.9 -171.7 
Arg -162 153.1 177.4 
trans 
Val -84.6 66.9 -159.7 
0 
Arg -87.5 60.9 -171.6 
Arg (i) -104.3 -23.6 -172.3 
D-Phe (i + 1) -165.9 142.4 152.9 
Pro (i + 2) 78.8 -58.6 -154.8 
Arg (i + 3) -85.4 69.9 175.6 




















Figure S2.7. Modelling images of gramicidin S and its mimetics 1-3 in the cis conformation (left) and 
the trans conformation (right).  
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Foreword 
This chapter extends our photopharmacological studies into antibacterial activity and reports on 
the design and synthesis of three short photoswitchable tetrapeptides (1-3) that specifically 
target Staphylococcus aureus (S. aureus). An azobenzene photoswitch was either incorporated 
into the side chain (peptides 1 and 2) or the C-terminus (peptide 3), to allow reversible switching 
between cis-enriched and trans-enriched photostationary states (PSS) when irradiated with light 
of a specific wavelength. Each PSS of peptides 1-3 was assayed against S. aureus, which 
revealed a contribution to antibacterial activity from several factors, such as hydrophobicity, net 
positive charge, azobenzene position, secondary structure, and amphiphilicity. Collectively, this 
work provides important fundamental insights for the design and synthesis of future 
antibacterial compounds.  
 
Figure 3.0. Three short photoswitchable peptides 1-3, with an azobenzene photoswitch incorporated 
either at the side chain or C-terminus, to allow reversible switching between the cis-enriched and trans-
enriched PSS.   
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3.1 Abstract 
Three photoswitchable tetrapeptides, based on a known synthetic antibacterial, were designed 
and synthesized to determine activity against Staphylococcus aureus (S. aureus). Each peptide 
contains an azobenzene photoswitch incorporated into either the N-terminal side chain (1), C-
terminal side chain (2), or the C-terminus (3), to allow reversible switching between cis-
enriched and trans-enriched photostationary states (PSS). Biological assays revealed the C-
terminal azobenzene (3) possessed the most potent antibacterial activity, with an MIC of 1 
µg/mL. In this study, net positive charge, hydrophobicity, position of the azobenzene, secondary 
structure, and amphiphilicity were all found to contribute to antibacterial activity, with each of 
these factors likely facilitating the peptide to disrupt the negatively charged bacterial lipid 
membrane. Hence, these short photoswitchable antibacterial tetrapeptides provide insights for 
the future design and synthesis of antibiotics targeting S. aureus.  
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3.2 Introduction 
Photopharmacology is an emerging strategy to modulate the bioactivity of a compound using a 
reversible molecular switch (photoswitch) to provide localized treatment of an associated 
disease.1-2 This approach offers an opportunity to mitigate off-target side effects,2-4 and in the 
context of an antibiotic, the development of resistance.2 This typically involves incorporating a 
photoswitch, such as an azobenzene, into a compound, such as a peptide, to induce a change in 
physical and chemical properties upon photoisomerization with light of a specific wavelength.5 
The use of light in this context can be fine-tuned with high spatiotemporal precision,1, 6-7 
allowing delivery of a bioactive compound. An azobenzene can be interconverted between the 
cis and trans isomers on irradiation with UV and visible light respectively, resulting in a 
significant change in configuration and dipole moment.8-9 Moreover, an azobenzene 
photoswitch provides a high photoisomerization yield, fast isomerization, low rate of 
photobleaching, and relative ease of synthesis.7, 10-12 We have previously reported 
photoswitching of an azobenzene-containing cyclic peptide based on a natural antibiotic, 
gramicidin S,13 along with the use of an azobenzene to regulate biosensors,14 protease 
inhibitors,15-16 and smart membranes.17 Herein, we present the design, synthesis, and evaluation 
against S. aureus of three photoswitchable tetrapeptides (1-3, Figure 3.1). An azobenzene 
photoswitch was incorporated into either the side chain (peptides 1 and 2) or the C-terminus 
(peptide 3) to explore the optimum position for photoswitching between trans-enriched and cis-
enriched PSS.   
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3.3 Results and Discussion 
The design of peptides 1-3 (Figure 3.1) is based upon a known compound by Lau et al.,18 
(compound 23, NH2-BRBR-CONH2, where B = p-phenyl-phenylalanine) which was reported 
to have antibacterial activity against methicillin-resistant S. aureus (MRSA, Minimal inhibitory 
concentration (MIC) 5 µg/ml).18 Peptides 1 and 2 each contain a p-phenylazophenylalanine 
azobenzene photoswitch, which closely mimics the structure of the biphenyl side chains of 
compound 23.18 Specifically, the N-terminal biphenyl of compound 2318 was replaced with an 
azobenzene photoswitch in peptide 1, while the C-terminal biphenyl was replaced with an 
azobenzene in peptide 2. Peptide 3 has the same azobenzene photoswitch directly attached to 
the C-terminus. The rational positioning of the azobenzene photoswitch into each of peptides 1-
3 allows retention of the overall positive charge (+3) in each case. The free amines located at 
the N-terminus and both side chains of each arginine residue remain available for protonation, 
and are crucial for antibacterial activity of compound 23 and other peptides targeting Gram-
positive bacteria18-19 through the establishment of electrostatic interactions for binding to the 
negatively charged bacterial membrane.20-22 The design of peptides 1-3 exploits the knowledge 
that the azobenzene photoswitch induces a change in dipole moment upon photoisomerization,8-
9, 23 which in turn affects the amphiphilicity24-25 that is crucial to antibacterial activity.13, 26 Each 
peptide was synthesized using standard Fmoc solid phase peptide synthesis (SPPS) as outlined 
in the Experimental section, and purified by RP-HPLC. The component azobenzene 
photoswitch was synthesized using an existing methodology.15  
Samples of peptides 1-3 were separately irradiated with visible light (405 nm) for 2h to yield 
the associated trans-enriched PSS, and the UV-Vis absorbance for each was reported (Figure 
S3.4). The trans-enriched PSS for each of peptides 1-3 showed an intense absorption band, with 
a maximum absorbance at 328 nm due to the symmetry-allowed π→π* transition. Each peptide 
was then exposed to UV light (352 nm) for 2h to give the associated cis-enriched PSS, and the 
absorbance spectra reported (Figure S3.4). The cis-enriched PSS for each of peptides 1-3 
exhibited a weak absorption at 428 nm resulting from the forbidden n→ π* transition, with a 
significantly reduced absorption at 328 nm. These absorbance values concur with literature, 
where both isomers of the azobenzene are known to give distinct but slightly overlapping 
absorption spectra.6, 27-28  
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Figure 3.1. Chemical structures for compound 2318 and peptide mimetics 1-3 (trans conformations are 
shown). The azobenzene photoswitch is highlighted in red. 
The maximum attainable amount for each PSS (photoisomerization yield) of peptides 1-3 was 
determined by 1H NMR analysis, particularly comparison of resonances corresponding to the 
para-substituted phenyl ring in the azobenzene photoswitch.13 Specifically, the resonances at δ 
7.85 ppm and δ 6.78 ppm for peptide 1, δ 7.81 ppm and δ 6.74 ppm for peptide 2, and δ 7.85 
ppm and δ 6.76 ppm for peptide 3 were used to calculate these ratios (Figures S3.11-S3.13). 
Relatively high photoisomerization yields for each PSS were observed, with trans-enriched PSS 
of 100%, 88%, and 85%, and cis-enriched PSS of 86%, 86%, and 91% for peptides 1-3 
respectively (Table 3.1). Detailed 1H NMR spectroscopy also confirmed the structural 
conformation of each peptide. Interestingly, 3JNH-CαH coupling constants between 7.5-10 Hz
29 
were observed for both cis-enriched and trans-enriched PSS of peptides 1-3, indicating the 
presence of a β-strand geometry for each (Table S3.2). To further define secondary structure, 
the cis and trans isomers of peptides 1-3 were analyzed by density functional theory (DFT). 
Calculated dihedral angles for both cis and trans isomers of peptides 1-3 were consistent with a 
β-strand conformation30 (Table S3.1, Figure S3.7), as per the 1H NMR data. Collectively, these 
findings indicate that the incorporation of an azobenzene photoswitch into either the side chain 
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or the C-terminus of the peptides does not result in a significant change in secondary structure 
upon photoisomerization. Thus, any differences in antibacterial activity are likely attributable 
to other factors, such as the azobenzene position and amphiphilicity, and these are discussed 
later.  
Half-lives for the cis-enriched PSS of each peptide were determined by measuring the kinetics 
of cis-trans thermal back isomerization, as detailed in the Supplementary Information. Briefly, 
samples of peptides 1-3 were each irradiated under UV light (352 nm) for 2.5h to provide the 
maximum attainable cis-enriched PSS. Each peptide in its cis-enriched PSS was then stored in 
the dark to switch to the respective trans-enriched PSS by thermal relaxation. The absorbance 
for each was measured every 10 min to monitor the change in absorbance at 328 nm, which is 
characteristic of the trans-enriched PSS. The half-life for each peptide was then calculated by 
extrapolating the curve, and the data analyzed using GraphPad Prism 8 software.31 The cis-
enriched PSS for each of peptides 1-3 possess comparable half-lives of 43.4h, 44.6h, and 40.8h 
respectively, thus affording sufficient time for antibacterial assaying against S. aureus (24h).  
Table 3.1. Photoisomerization yields and half-lives of peptide mimetics 1-3, in their respective 
photostationary states (PSS). 
Peptide 
Photoisomerization yield (%) 
Half-life for cis-
enriched PSS (h) trans-enriched PSS cis-enriched PSS 
1 100 86 43.4 
2 88 86 44.6 
3 85 91 40.8 
The two photostationary states of peptides 1-3 were assayed against S. aureus ATCC 49775 
(see 3.7.3.10 Biological Assays), as model compound 2318 is active against this bacterial species. 
Each peptide was dissolved in DMSO at a concentration of 8 mg/mL, and irradiated separately 
using either UV (352 nm) or Vis (405 nm) light for 2h to obtain the respective cis-enriched and 
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trans-enriched PSS, which were then subjected to antimicrobial susceptibility assays.32 Peptide 
1, containing an azobenzene moiety to mimic the N-terminal biphenyl side chain of synthetic 
tetrapeptide (compound 2318), displayed a modest antibacterial activity with MICs of 16 µg/mL 
and 64 µg/mL for the trans-enriched and cis-enriched PSS respectively (Table 3.2). 
Replacement of the C-terminal biphenyl side chain moiety with an azobenzene photoswitch, as 
in peptide 2, increased antibacterial activity with MICs of 8 µg/mL and 32 µg/mL for the trans-
enriched and cis-enriched PSS, respectively. As peptides 1 and 2 both possess an identical amino 
acid composition and similar secondary structure, these disparate antibacterial properties likely 
reflect the influence of the position of the azobenzene photoswitch. However, a four-fold 
difference in the MIC values between the cis-enriched and trans-enriched PSS of peptides 1 and 
2 was observed (Table 3.2), suggesting that in addition to the specific location of the azobenzene 
moiety, the intrinsic properties of the photoswitch contribute to antibacterial activity. This four-
fold disparity is likely due to a change in overall amphiphilicity,13 as the azobenzene 
photoswitch induces a considerable change in the dipole moment upon photoisomerization.8-9 
As the trans-enriched PSS of peptides 1 and 2 most closely resemble the structure of the 
synthetic tetrapeptide (compound 2318), it was not surprising that these were more active in 
suppressing the growth of S. aureus than their cis-enriched counterparts. Notably, the trans-
enriched PSS of peptide 3 exhibited far superior antibacterial activity over peptides 1 and 2, 
with a particularly potent MIC of 1 µg/mL against S. aureus, again demonstrating the 
significance of the position of the azobenzene photoswitch. The cis-enriched PSS of peptide 3 
was found to be insoluble in the assay medium, which further supports a change in 
hydrophobicity and overall amphiphilicity upon photoisomerization. Furthermore, the 
additional aromatic groups in peptide 3 increased the hydrophobicity of the compound in 
comparison to peptides 1 and 2, as evidenced by the longer retention time observed by RP-
HPLC (Figure S3.3). Placement of the azobenzene photoswitch at the C-terminus of peptide 3 
provides increased hydrophobicity without altering the net positive charge, thus affording 
optimum amphiphilicity. These properties are clearly advantageous for the designed peptide to 
disrupt the bacterial lipid membrane, thereby providing a practical insight into the possible 
mechanism for antibacterial activity. 
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Table 3.2. Minimum inhibitory concentration (MIC) for the trans-enriched and cis-enriched PSS of 
peptide mimetics 1-3 against S. aureus ATCC 49775. The MIC for the cis-enriched PSS of peptide 3 
was not determined due to its insolubility in the assay medium. (* ND – not determined) 
Peptide mimetics 
Minimum Inhibitory Concentration (MIC) (µg/mL) 
trans-enriched PSS cis-enriched PSS 
1 16 64 
2 8 32 
3 1 ND* 
3.4 Conclusion 
In summary, three short photoswitchable antibacterial peptides, based on a known synthetic 
tetrapeptide, were designed and synthesized to investigate antibacterial activity against S. 
aureus. Each peptide (1-3) contains an azobenzene photoswitch incorporated either on a side 
chain (1-2) or the C-terminus (3), to allow reversible switching between the cis-enriched and 
trans-enriched PSS. Biological testing against S. aureus revealed a four-fold difference in the 
antibacterial activity between the cis-enriched and trans-enriched PSS of peptides 1 and 2, 
revealing a change in overall amphiphilicity brought about by a change in dipole moment upon 
photoisomerization. A two-fold difference in the antibacterial activity between peptides 1 and 2 
was also observed, and attributed to the positioning of the azobenzene photoswitch, as both 
peptides contain an identical amino acid composition and similar secondary structure as defined 
by the earlier 1H NMR analysis and modelling. In each case, the trans-enriched PSS was more 
potent than its cis-enriched counterpart, as it most closely mimics the structure of the biphenyl 
side chain of the known antibacterial. The trans-enriched PSS of peptide 3 exhibited the most 
potent antibacterial activity, with an MIC of 1 µg/mL against S. aureus. The position of the 
azobenzene photoswitch is also conspicuous in 3, as it allows an increase in hydrophobicity 
within the peptide without disrupting the net positive charge. Hydrophobicity and an overall 
positive charge are clearly desirable properties to enable the peptide to disrupt the negatively 
charged bacterial lipid membrane of S. aureus. Furthermore, as each cis-enriched and trans-
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enriched PSS for each peptide was found to contain a β-strand geometry, it is likely that this 
well-defined secondary structure provides the fundamental framework to stabilize the amino 
acid residues responsible for maintaining amphiphilicity. Hence, an overall positive charge, 
hydrophobicity, azobenzene position, and amphiphilicity were all found to be crucial in 
promoting antibacterial activity. 
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3.7 Supplementary Information 
3.7.1 Materials 
Dichloromethane (CH2Cl2), N,N‐dimethylformamide (DMF), methanol (MeOH), and 
piperidine were purchased from Merck, Australia. Nitrosobenzene, 1-propanephosphonic 
anhydride solution (T3P), trifluoroacetic acid (TFA), N-methylmorpholine, triiosopropylsilane 
(TIPS), 1,4-dioxane and diisopropylethylamine (DIPEA) were purchased from Sigma-Aldrich, 
Australia. Magnesium sulphate (MgSO4), hydrochloric acid (HCl), ethyl acetate and acetic acid 
were purchased from Chem Supply, Australia. 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), Fmoc-4-amino-L-
phenylalanine, and Boc-L-Ala(4,4’-biphenyl)-OH, Fmoc-Arg(Pbf)-OH, and 2-Chlorotrityl 
chloride resin were purchased from Chem-Impex International, Inc., USA. Sieber amide resin 
was purchased from GL Biochem (Shanghai) Ltd. Acetonitrile was purchased from Thermo 
Fisher Scientific, Inc., Australia. All solvents and reagents were used without purification unless 
noted. 
3.7.2 Methods 
High Performance Liquid Chromatography (HPLC) 
The peptide mimetics 1-3 were analyzed and purified by reverse phase high performance liquid 
chromatography (RP-HPLC), using a Gilson purification system equipped with a UV-Vis 
absorbance detector and a Supelco Analytical C18 column (Discovery BIO Wide Pore C5-5, 250 
x 10 mm, 5 μm). Aqueous solvent A: Water:TFA (100:0.1 v/v) and organic solvent B: 
ACN:TFA (100:0.08 v/v) were used during the purification process.   
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Mass Spectrometry 
High resolution mass spectral data were obtained using an Agilent 6230 TOF LC/MS mass 
spectrometer. Mass spectra were obtained over a range of 100 < m/z < 2000.  
UV-Vis Spectrophotometry 
All UV-Vis spectra were obtained at 25 ± 0.5°C on the Synergy H4 Hybrid Multi-Mode 
Microplate Reader. All measurements were performed in a 96-well plate with a concentration 
of approximately 100 μg/mL of 1-3 in DMSO. For conversion from a trans to a cis conformation, 
1-3 were irradiated for 1h, under a UV lamp (UVP® MRL-58, 8 W, 352 nm) prior to 
measurement. For conversion from the cis to trans conformation, visible light (405 nm) was 
used. The absorbances for the respective conformations of 1-3 were measured between 200 – 
800 nm.  
NMR Spectroscopy 
¹H NMR spectrum of the azobenzene photoswitch was recorded in DMSO-d6 solution using an 
Agilent DD2 500MHz spectrometer. ¹H NMR spectra of the peptide mimetics 1-3 were recorded 
on an Agilent DD2 600MHz NMR spectrometer. Chemical shifts are reported in ppm (δ) using 
TMS (0.00 ppm) as the internal standard. Signals are recorded as s (singlet), d (doublet), t (triplet) 
or m (multiplet). 
Molecular Modelling 
The lowest energy conformation for cis and trans isomers of peptides 1-3 were determined in 
collaboration using Gaussian 091 package on the National Computing Infrastructure (NCI) 
National Facility, e.g. Raijin supercomputer. The initial geometries of peptides 1-3 were 
constructed through GaussView 5.0 program. The geometry of each structure was optimized in 
the gas phase using the density functional theory (DFT) with the B3LYP density function and 
basis sets of increasing size from STO-3G up to 6-31G** for all atoms.  
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3.7.3 Experimental 
3.7.3.1 Synthesis of (E)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-
(phenyldiazenyl)phenyl)propanoic acid 
 
To a stirring solution of nitrosobenzene (1.1 g, 10.3 mmol) in glacial acetic acid (85 mL), Fmoc-
4-amino-L-phenylalanine (4.6 g, 11.3 mmol) was added, and the mixture was refluxed at 40 °C 
for 24h. Water (100 mL) was added to the mixture, and the precipitate was filtered and dried 
under vacuum. The crude product was purified by column (8:2 CH2Cl2/MeOH) to give an 
orange solid (4.89 g, 97%). 1H NMR (500 MHz, DMSO-d6): δ 7.87 (d, J = 7.8 Hz, 4H), 7.82 (d, 
J = 8.3 Hz, 2H), 7.76 (d, J = 8.5 Hz, 1H), 7.64-7.54 (m, 5H), 7.50 (d, J = 8.1 Hz, 2H), 7.41-7.36 
(m, 2H), 7.31-7.26 (m, 2H), 4.28-4.24 (m, 1H), 4.22 (d, J = 7.0 Hz, 2H), 4.17 (t, J = 6.4 Hz, 
1H), 3.20 (dd, J = 13.7, 4.3 Hz, 1H), 2.99 (dd, J = 13.6, 10.8 Hz, 1H). HRMS: m/zcalc for 
C30H25N3O4 = 492.1918 [M+H
+], m/zfound = 492.1917.  
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3.7.3.2 Synthesis of tert-butyl (E)-(4-(phenyldiazenyl)benzyl)carbamate 
 
To a stirring solution of nitrosobenzene (1.0 g, 9.3 mmol) in glacial acetic acid (50 mL), Boc-
L-Ala(4,4’-biphenyl)-OH (2.1 g, 9.4 mmol) was added, and the mixture was stirred at rt for 24h. 
Water (50 mL) was added to the mixture, and the precipitate was filtered and dried under 
vacuum to give an orange solid (2.8 g, 97%). 1H NMR (500 MHz, DMSO-d6): δ 7.89-7,85 (m, 
4H), 7.62-7.54 (m, 3H), 7.50-7.44 (m, 3H), 4.23 (d, J = 6.0 Hz, 2H), 1.41 (s, 9H). HRMS: m/zcalc 
for C18H21N3O2 = 312.1707 [M+H
+], m/zfound = 312.1705. 




acid was dissolved in a mixture of 1M HCl/dioxane, and the mixture was stirred at rt for 1h. The 
solvent was removed under N2 flow, and the residue was purified by column (7:3 CH2Cl2/MeOH) 
to give a quantitative yield of an orange solid. 1H NMR (500 MHz, DMSO-d6): δ 8.32 (br s, 
2H), 7.96-7.94 (m, 2H), 7.92-7.90 (m, 2H), 7.69-7.67 (m, 2H), 7.64-7.57 (m, 3H), 4.16 (s, 2H). 
HRMS: m/zcalc for C13H13N3 = 212.1182 [M+H]
+, m/zfound = 212.1185.  
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3.7.3.4 Solid Phase Peptide Synthesis (SPPS)  
Peptides 1-2 
Standard Fmoc-based SPPS and commercially available reagents were used for the synthesis of 
peptides 1-2 using the Sieber amide resin with a loading of (0.4 mmol/g, 1.0 g, 1 equiv.). The 
resin was swelled in DMF (25 mL) for 1h before the deprotection of Fmoc using 25% 
piperidine/DMF (2 x 25 mL) for 30 min. The resin was then washed with CH2Cl2 (x3), DMF 
(x3), and CH2Cl2 (x3). The unreacted active sites on the resin were capped with 3:2 acetic 
anhydride/pyridine (2 x 25 mL), and the capping solution was allowed to stand for 30 min before 
washing the resin with CH2Cl2 (x3), DMF (x3) and CH2Cl2 (x3). Couplings of the amino acids 
and azobenzene photoswitch on the Sieber amide resin were performed using the following 
molar ratios of reagents: Fmoc-amino acids and Fmoc-azobenzene photoswitch (2 equiv.) 
dissolved in 20% N-methylmorpholine/DMF (20 mL), and HATU (2 equiv.). N-Fmoc 
deprotection was carried out by treating the resin with 25% piperidine/DMF (25 mL) for 30 min 
before washing with CH2Cl2 (x3), DMF (x3) followed by CH2Cl2 (x3). Coupling and 
deprotection procedures were repeated alternatively until the sequence was completed. The 
linear peptides 1-2, together with Pbf protecting groups on the side chain of arginine residues 
were cleaved from the resin using TFA/TIPS/CH2Cl2 (95:2.5:2.5, 20 mL). The reagents were 
left to stand for 1h with stirring before filtering the peptide solution. The volatile products from 
the filtrate were removed by N2 flow, and the linear peptides 1-2 were placed under vacuum for 
1h, to yield an orange solid. All crude products were purified by RP-HPLC to give an orange 
solid. HRMS: Peptide 1: m/zcalc for C42H53N13O4 = 804.4419 [M+H]
+, m/zfound =804.4416. 
Peptide 2: m/zcalc for C42H53N13O4 = 804.4419 [M+H]
+, m/zfound =804.4416. 
Linear precursor for peptide 3 
Standard Fmoc-based SPPS and commercially available reagents were used for the synthesis of 
the precursor for peptide 3 using the 2-Chlorotrityl chloride resin. Resin preloaded with Fmoc-
Arg-OH (0.4 mmol/g, 1.0 g, 1 equiv.) was used to synthesize the linear precursor. The unreacted 
active sites on the resin were capped with a solution of 17:2:1 CH2Cl2/MeOH/DIPEA (2 x 25 
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mL). The capping solution was allowed to stand for 30 min before washing the resin with 
CH2Cl2 (x3), DMF (x3), and CH2Cl2 (x3). N-Fmoc deprotection was carried out by treating the 
resin with 25% piperidine/DMF (25 mL) for 30 min before washing with CH2Cl2 (x3), DMF 
(x3), followed by CH2Cl2 (x3). For the couplings of the amino acids, the following molar ratios 
of reagents were used: Fmoc-amino acid/Boc-amino acid (2 equiv.) dissolved in DMF (20 mL), 
0.5 M HATU/DMF, and DIPEA (8 equiv.). The resin was washed with CH2Cl2 (x3), DMF (x3), 
followed by CH2Cl2 (x3), and the coupling procedures were repeated. The coupling time in all 
cases was 2h. Deprotection and coupling procedures were repeated alternatively until the 
sequence was completed. After the peptide sequences were completed and deprotected, the resin 
was washed with CH2Cl2 (x3), DMF (x3), followed by CH2Cl2 (x3), and dried under vacuum. 
For the cleavage of the linear precursor from the resin, a solution of 1.5% TFA/CH2Cl2 (2 x 20 
mL) was used while maintaining the N-terminus Boc protecting group and the side chain 
protections of arginine residues. The reagents were left to stand for 15 min with stirring before 
filtering the peptide solution. The volatile products from the filtrate were removed by N2 flow, 
and the linear precursor was placed under vacuum for 1h, to yield a yellow solid.   
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3.7.3.5 Coupling of linear precursor of peptide 3 and (E)-(4-
(phenyldiazenyl)phenyl)methanamine 
 
To a stirring solution of the linear precursor of peptide 3 (0.8 g, 0.6 mmol), DIPEA (1.1 mL, 6.0 
mmol), and T3P® (50% in ethyl acetate, 0.4 g, 1.2 mmol) in ethyl acetate (20 mL), (E)-(4-
(phenyldiazenyl)phenyl)methanamine (0.1 g, 0.6 mmol) was added, and the mixture was stirred 
for 24h at rt. The solvent was removed in vacuo to give an orange precipitate. HRMS: m/zcalc 
for C86H103N13O12S2 = 1574.7364 [M+H]
+, m/zfound =1574.7356. 
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3.7.3.6 Deprotection of Boc and Pbf Protecting Groups to yield peptide 3 
 
All protecting groups were deprotected using 95% TFA/CH2Cl2 (10 mL) for 1h at rt. The 
solvents were removed in vacuo, and the residue was purified by RP-HPLC to give an orange 
solid. HRMS: m/zcalc for C55H63N13O4 = 970.5199 [M+H]
+, m/zfound = 970.5239. 
3.7.3.7 Photoisomerization of Peptides 1-3 
Peptides 1-3 were dissolved in DMSO at a concentration of 100 μg/mL and exposed to visible 
light of 405 nm for 2h to yield the trans-enriched PSS. The trans-enriched PSS of 1-3 were 
irradiated by UV light of 352 nm for 2h, to convert to the respective cis-enriched PSS.  
3.7.3.8 Half-Life Analysis of Peptides 1-3 
The half-life of peptides 1-3 was determined by measuring the kinetics of cis-trans thermal back 
isomerization, characterized using UV-Vis spectrophotometry. Prior to irradiation, peptides 1-
3 in their thermally stable trans-enriched PSS were dissolved in DMSO, and the wavelengths 
of maximum absorbance (λmax) were measured using a Synergy H4 Hybrid Multi-Mode 
Microplate Reader. The peptides were then irradiated under UV light (352 nm) for 2h to convert 
the samples to their cis-enriched PSS, and the λmax were determined. The samples were 
irradiated under UV (352 nm) for a further 30 min to achieve the maximum attainable cis-
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enriched PSS, which was confirmed when no further increase was observed in the absorbance 
at the λmax. Each peptide in its cis-enriched PSS was then stored in the dark to switch to the 
respective trans-enriched PSS by thermal relaxation. The absorbance for each peptide was 
measured every 10 min to monitor the change in the absorbance at 328 nm, which is 
characteristic of the trans-enriched PSS. The measurements were conducted over a period of 
64h. The half-life for each peptide was then calculated by extrapolating the curve, and the data 
analyzed using GraphPad Prism 8 software.2  
3.7.3.9 Molecular Modelling 
The lowest energy structures for the cis and trans isomers of peptides 1-3 were determined in 
the gas phase using the NWChem 6.6 package,3 with tight convergence criteria using a hybrid 
B3LYP functional with 6-31G** basis set for all atoms. The initial geometries of peptides 1-3 
were constructed through the GaussView 5.0 package. Conformational analyses of the dihedral 
angles were conducted using the Chimera 1.14 software.4  
3.7.3.10 Biological Assays (Antibacterial Susceptibility Evaluation) 
Antibacterial activity was determined by the microdilution broth method as recommended by 
the CLSI (Clinical and Laboratory Standards Institute, Document M07-A8, 2009, Wayne, PA.) 
using cation-adjusted Mueller-Hinton broth (Trek Diagnostics Systems, U.K.). Serial two-fold 
dilutions of each peptide were made using DMSO as the diluent. Specifically, the concentration 
range for the antibacterial peptides in the assays was an 8-point two-fold dilution series, starting 
at 128 µg/ml (i.e. 128, 64, 32, 16, 8, 4, 2, 1 µg/ml). Trays were inoculated with 5 x 104 CFU of 
Staphylococcus aureus ATCC 49975 in a volume of 100 μL (final concentration of DMSO was 
3.2% (v/v)) and incubated at 37 °C for 24h. Growth of the bacterium was quantified by 
measuring the absorbance at 620 nm. 
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3.7.4 HPLC Chromatograms 
 
Figure S3.1. HPLC chromatogram for peptide 1, visualized at 320 nm. The retention time for peptide 1 
was found to be 15.8 min. 
 
Figure S3.2. HPLC chromatogram for peptide 2, visualized at 320 nm. The retention time for peptide 2 
was found to be 15.8 min. 
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Figure S3.3. HPLC chromatogram for peptide 3, visualized at 320 nm. The retention time for peptide 3 
was found to be 17.0 min.  
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3.7.5 UV-Vis Spectra 
 
Figure S3.4. UV-Vis spectra for peptides 1-3 in the trans-enriched PSS (blue) and cis-enriched PSS (red) 
after 2 hours of irradiation under Vis (405 nm) and UV (352 nm) respectively. The trans-enriched PSS 
shows a maximum absorbance at 328 nm, while the cis-enriched PSS shows a higher absorbance at 428 
nm, and a much lower absorbance at 328 nm. 








Figure S3.5. UV-Vis spectra for peptides 1-3 before (blue) and after (red) UV irradiation for 15 min. 
The high intensity of absorbance at 328 nm shows that peptides 1-3 existed predominantly in the trans 
conformation prior to UV irradiation. The absorbance at 328 nm decreases drastically upon UV exposure 
for 15 min, indicating successful photoconversion of the peptides into the cis conformation.  
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3.7.6 Half-Life Analysis 
 
Figure S3.6. The absorbance curves of peptides 1-3 at their respective λmax when left in the dark for 64h. 
The gradual increase in the absorbance at 328 nm indicates the cis-trans thermal back isomerization of 
the peptide samples.  
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3.7.7 Molecular Modelling 
Table S3.1. Phi (ϕ) and psi (ψ) dihedral angles for the trans and cis isomers of peptides 1-3. A typical 
β-strand is characterized with -160° < ϕ < -100° and 90° < ψ < 160°.5  
Peptide Isomer Cα 
Dihedral angle (°) β-strand 
content (%) ϕ ψ 
1 
trans 
Azobenzene - 136.8 
100 
Arginine -142.2 149.6 
p-phenyl-phenylalanine -108.1 141.5 
Arginine -138.1 132.0 
cis 
Azobenzene - 130.6 
100 
Arginine -150.3 155.0 
p-phenyl-phenylalanine -119.2 144.0 
Arginine -142.7 134.7 
2 
trans 
p-phenyl-phenylalanine - 137.6 
71 
Arginine -158.2 172.2 
Azobenzene -142.5 174.1 
Arginine -152.1 156.2 
cis 
p-phenyl-phenylalanine - 142.1 
86 
Arginine -153.3 172.3 
Azobenzene -124.5 152.4 
Arginine -150.8 153.2 
3 
trans 
p-phenyl-phenylalanine - 152.8 
71 
Arginine -149.2 146.9 
p-phenyl-phenylalanine -47.3 129.9 
Arginine -141.8 61.4 
cis 
p-phenyl-phenylalanine - 152.7 
71 
Arginine -149.6 148.6 
p-phenyl-phenylalanine -46.3 129.7 
Arginine -142.1 54.5 
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Peptide 1 
    
Peptide 2 
   
Peptide 3 
Figure S3.7. Molecular models showing the presence of β-strand conformation for the trans (left) and 
cis (right) isomers of peptides 1-3.  
114 | P a g e  
  
3.7.8. 1H NMR Spectroscopy 
Table S3.2. 3JNH-CαH values for the amide NH in peptides 1-3. 3JNH-CαH values of 7.5-10 Hz indicate the 








trans 8.0 (Arg), 8.0 (Biphenylalanine), 8.3 (Arg) 100 
cis 8.1 (Arg), 8.3 (Biphenylalanine), 10.7 (Arg) 67 
2 
trans 8.0 (Arg), 7.9 (Azobenzene), 8.1 (Arg) 100 
cis 7.9 (Arg), 7.9 (Azobenzene), 7.9 (Arg) 100 
3 
trans 
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Figure S3.8. 1H NMR spectrum for (E)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-
(phenyldiazenyl)phenyl)propanoic acid. 
 
Figure S3.9. 1H NMR spectrum for tert-butyl (E)-(4-(phenyldiazenyl)benzyl)carbamate. 




Figure S3.10. 1H NMR spectrum for (E)-(4-(phenyldiazenyl)benzyl)carbamate. 
  




Figure S3.11. 1H NMR spectra for the trans-enriched (blue) and cis-enriched (red) PSSs of peptide 1.  




Figure S3.12. 1H NMR spectra for the trans-enriched (blue) and cis-enriched (red) PSSs of peptide 2.  




Figure S3.13. 1H NMR spectra for the trans-enriched (blue) and cis-enriched (red) PSSs of peptide 3.  
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Foreword 
While Chapters 2 and 3 focus on a photopharmacological approach to control antibacterial 
activity, this chapter emphasizes an alternative strategy, specifically the design and synthesis of 
a hypoxia-activated prodrug to modulate antibacterial activity. Hypoxia is a condition resulting 
from oxygen deficiency found in certain bacterial-infected tissues. This unique 
microenvironmental feature allows for a hypoxia-activated prodrug strategy to regulate the 
activity of an antibiotic, such that the active agent is only released under reductive conditions 
that mimic hypoxia. This chapter reports a prodrug based on a known antibacterial compound 
to target Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) under such reductive 
conditions. Prodrug 2 was synthesized by masking the N-terminus and side chain amines of a 
component lysine residue as 4-nitrobenzyl carbamates, while activation to liberate the active 
antibacterial 1 was demonstrated on treatment with a model reductant, tin(II) chloride. 
Antibacterial susceptibility assays were performed to confirm the bioactivities of the prodrug 
and its corresponding active component.  
 
Figure 4.0. Reductive elimination of the 4-nitrobenzyl carbamate protecting groups in prodrug 2 to 
reveal the free amines in 1 for antibacterial activity against S. aureus and E. coli. This concept potentially 
allows for active control over the delivery of antibiotics that otherwise may pose limitations such as 
toxicity and bioavailability.  
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4.1 Abstract 
A prodrug based on a known antibacterial compound is reported to target Staphylococcus aureus 
(S. aureus) and Escherichia coli (E. coli) under reductive conditions. The prodrug was prepared 
by masking the N-terminus and side chain amines of a component lysine residue as 4-
nitrobenzyl carbamates. Activation to liberate the antibacterial was demonstrated on treatment 
with a model reductant, tin(II) chloride. The bioactivity of 1 was confirmed in antibacterial 
susceptibility assays, whereas prodrug 2 was inactive.   
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4.2 Introduction 
Tissue hypoxia is a common microenvironmental hallmark associated with bacterial infection.1 
Animal studies have demonstrated that hypoxia is associated with a range of bacterial infections, 
with low levels of oxygen caused by reduced blood supply to the infected tissue.2-3 Hypoxia-
activated prodrugs present as a strategy to regulate the activity of an antibiotic, such that the 
active agent is only released under conditions of low oxygen, as found in certain bacterial-
infected tissues.4-5 This limits general exposure to the active agent, thereby mitigating possible 
undesirable side effects. Importantly, it can potentially improve the efficacy of treatment as the 
active antibacterial is delivered specifically to the site of infection and not to the healthy 
microflora. Improved drug delivery, such as this, can also suppress antibiotic resistance. Proof 
of concept studies have demonstrated that hypoxia-activated prodrugs can effectively target 
cancer tumors that likewise experience hypoxic environments.6-9 However, similar studies on 
bacterial-infected tissue are scarce.10 Such prodrugs typically mask a key functional group 
within the parent active drug with a protecting group that is susceptible to reduction under 
hypoxic conditions. This then allows for site-specific release of the active drug.11 
A number of protecting groups susceptible to cleavage under hypoxia12-13 have been employed 
in the design and development of prodrugs. In this conceptual study, we exploit the unique 
hypoxic environment associated with bacterial-infected tissue with the design and synthesis of 
antibacterial prodrug 2 (Figure 4.1) that is specifically activated under reductive conditions. The 
prodrug is based on the proven broad-spectrum antibacterial 114, which was chosen to provide 
the appropriate functionality to allow attachment of a group activated under hypoxic conditions 
to successfully target both Gram-positive bacteria, S. aureus, and Gram-negative E. coli. 
Furthermore, it is known to be nontoxic towards mammalian cells.14 Antibacterial 1 possesses 
a lysine residue with free amines at both the N-terminus and side chain that are essential for its 
bioactivity. Once protonated, these groups establish electrostatic interactions between the 
antibacterial agent and the negatively charged bacterial membrane.15-17 In this study, the amines 
were masked with nitrobenzylocarbonyl moieties in 2 to neutralize the electrostatic charge of 
the compound, thereby abolishing binding to the bacteria. Subsequent removal of the protecting 
groups under conditions that mimic hypoxia is proposed to restore the binding interaction and 
antibacterial activity. Previous studies utilized similar nitrobenzyl protecting groups to 
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synthesize numerous prodrugs, which were shown to be significantly less toxic than the active 
component in vitro and in vivo.18-20 Reduction of prodrug 2 would likely occur in the hypoxic 
extracellular environment where it can target the bacterial membrane. The nitro group reduction 
strategy was purposely chosen here as it is well known to work in cellular and extracellular 
hypoxic environments.21-23 
 
Figure 4.1. Structures of the active antibacterial 114 and inactive prodrug 2.  
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4.3 Results and Discussion 
Prodrug 2 was synthesized using standard solution-based chemistry, as detailed in the 
Experimental section of the Supplementary Information. Briefly, lysine was reacted with two 
equivalents of 4-nitrobenzyl chloroformate in the presence of sodium bicarbonate/dioxane to 
give bis 4-nitrobenzylocarbonyl-protected 4 (Scheme 4.1). 10-Chloro-9-anthraldehyde was 
reacted with octylamine, and the resulting intermediate imine reduced and acidified to give 3. 
Compounds 3 and 4 were then coupled using HBTU and DIPEA in DMF/CHCl3 to give the 
desired prodrug 2, which was purified using reverse-phase HPLC, and characterized by 1H 
NMR. 
 
Scheme 4.1. Synthesis of antibacterial prodrug 2. Reagents (i) dioxane/Na2CO3, rt, 16h, (ii) C8H17NH2, 
MeOH, 6h, then NaBH4, MeOH, 18h, followed by 4M HCl, (iii) DIPEA, HBTU, DMF/CHCl3 (5:3), rt, 
24h.  
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We next demonstrated that the nitrobenzylocarbonyl protecting groups of prodrug 2 could be 
removed on reduction with tin(II) chloride as a mimic of hypoxia to reveal the active 
antibacterial agent 1 (Scheme 4.2). The product was then purified using reverse-phase HPLC, 
and characterized by 1H NMR and high resolution mass spectrometry (HRMS). In addition, 1 
gave a characteristic emission between 400-500 nm of some ten-fold greater intensity than 2 
(Figure 4.2). This is consistent with quenching from the nitrobenzylocarbonyl groups due to 
intramolecular photoinduced electron transfer (PET).24 Collectively, these results confirm the 
successful reduction and removal of the 4-nitrobenzylocarbonyl groups from the prodrug 2 to 
reveal the active antibacterial 1 under conditions that mimic environmental hypoxia.  
 
Scheme 4.2. Reduction of antibacterial prodrug 2 to reveal the active antibacterial 114. Reagents (i) 
SnCl2.2H2O (20 eq.), dry CHCl3, dry MeOH, 50 °C, 22h.  
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Figure 4.2. Emission spectra for the prodrug 2 (blue) and active antibacterial 1 (green), measured 
between 400-600 nm, with an excitation wavelength of 380 nm. 
Prodrug 2 and active antibacterial 1 were separately assayed against Gram-positive S. aureus 
ATCC 49775 and Gram-negative E. coli K 12, in accordance with protocol25 detailed in the 
Experimental section of the Supplementary Information. In brief, two-fold serial dilutions were 
made for each compound and separately inoculated with both bacteria at 37°C for 16-20 hours. 
The lowest concentration that inhibited bacterial growth was reported as the minimal inhibitory 
concentration (MIC). As expected, compound 1 was active against both bacteria and yielded 
MICs of 2 µg/mL and 4 µg/mL against S. aureus and E. coli, respectively, consistent with the 
potencies previously reported.14 In contrast, prodrug 2 was inactive against both species at the 
highest tested concentration (256 µg/mL, Table 4.1). These data confirm the importance of the 
free amines for antibacterial activity. Our goal was to demonstrate that liberation of the active 
antibacterial agent 1 from prodrug 2 can kill these bacteria, which was successfully achieved.  
Table 4.1. Antibacterial activity of 1 and 2 against S. aureus and E. coli. 
  
Minimum inhibitory concentration, MIC 
(µg/mL) 
Prodrug 2 Active antibacterial 1 
S. aureus ATCC 49775 > 256 2 
E. coli K 12 > 256 4 
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4.4 Conclusion 
In summary, prodrug 2 has been synthesized and shown to be inactive against both S. aureus 
ATCC 49775 and E. coli K 12, with the active agent 1 revealed on chemical reduction. This 
study models a hypoxia-activated strategy to control antibacterial activity, and is potentially the 
first step towards a hypoxia-activated antibiotic to allow localized treatment, improved efficacy, 
and suppression of bacterial resistance. It is anticipated that this work will provide further 
opportunities for cellular studies with bioreductive prodrugs that target bacterial-infected tissue. 
4.5 Acknowledgements 
This work was supported by the Australian Research Council (CE140100003). We also 
acknowledge the Australian National Fabrication Facility for providing the analytical facilities 
used in this work. SWP was supported by the National Health and Medical Research Council 
of Australia (GN1147538).  
133 | P a g e  
  
4.6 References 
(1) Schaffer, K.; Taylor, C. T., The impact of hypoxia on bacterial infection. FEBS J. 2015, 
282 (12), 2260−2266. 
(2) Colgan, S. P.; Taylor, C. T., Hypoxia: an alarm signal during intestinal inflammation. 
Nat. Rev. Gastroenterol. Hepatol. 2010, 7 (5), 281−287. 
(3) Worlitzsch, D.; Tarran, R.; Ulrich, M.; Schwab, U.; Cekici, A.; Meyer, K. C.; Birrer, P.; 
Bellon, G.; Berger, J.; Weiss, T.; Botzenhart, K.; Yankaskas, J. R.; Randell, S.; Boucher, R. C.; 
Döring, G., Effects of reduced mucus oxygen concentration in airway Pseudomonas infections 
of cystic fibrosis patients. J. Clin. Invest. 2002, 109 (3), 317−325. 
(4) Yang, H.; Sha, W.; Liu, Z.; Tang, T.; Liu, H.; Qin, L.; Cui, Z.; Chen, J.; Liu, F.; Zheng, 
R.; Huang, X.; Wang, J.; Feng, Y.; Ge, B., Lysine acetylation of DosR regulates the hypoxia 
response of Mycobacterium tuberculosis. Emerg. Microbes Infect. 2018, 7 (1), 34. 
(5) Fu, Q.; Yang, Y. J.; Li, C.; Zeng, Q. F.; Zhou, T.; Li, N.; Liu, Y.; Liu, S. K.; Liu, Z. J.; 
The CC and CXC chemokine receptors in channel catfish (Ictalurus punctatus) and their 
involvement in disease and hypoxia responses. Dev. Comp. Immunol. 2017, 77, 241–251. 
(6) Albertella, M. R.; Loadman, P. M.; Jones, P. H.; Phillips, R. M.; Rarnpling, R.; Burnet, 
N.; Alcock, C.; Anthoney, A.; Vjaters, E.; Dunk, C. R.; Harris, P. A.; Wong, A.; Lalani, A. S.; 
Twelves, C. J., Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with 
solid tumors: Results of a phase I study. Clin. Cancer Res. 2008, 14 (4), 1096–1104. 
(7) Cazares-Körner, C.; Pires, I. M.; Swallow, I. D.; Grayer, S. C.; O'Connor, L. J.; Olcina, 
M. M.; Christlieb, M.; Conway, S. J.; Hammond, E. M., CH-01 is a Hypoxia-Activated Prodrug 
That Sensitizes Cells to Hypoxia/Reoxygenation Through Inhibition of Chk1 and Aurora A. 
ACS Chem. Biol. 2013, 8 (7), 1451–1459.  
(8) Jameson, M. B.; Rischin, D.; Pegram, M.; Gutheil, J.; Patterson, A. V.; Denny, W. A.; 
Wilson, W. R., A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia 
and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother. Pharmacol. 
2010, 65 (4), 791–801. 
(9) Wang, J.; Foehrenbacher, A.; Su, J.; Patel, R.; Hay, M. P.; Hicks, K. O.; Wilson, W. R., 
The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive 
Prodrug CEN-209 under Hypoxia. Clin. Cancer Res. 2012, 18 (6), 1684–1695. 
134 | P a g e  
  
(10) Denny, W. A.; Palmer, B. D., The nitroimidazooxazines (PA-824 and analogs): 
structure-activity relationship and mechanistic studies. Future Med. Chem. 2010, 2 (8), 1295–
1304. 
(11) Testa, B., Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps. Curr. Opin. 
Chem. Biol. 2009, 13 (3), 338–344. 
(12) Eom, T.; Yoo, W.; Lee, Y. D.; Park, J. H.; Choe, Y.; Bang, J.; Kim, S.; Khan, A., An 
activatable anticancer polymer-drug conjugate based on the self-immolative azobenzene motif. 
J. Mater. Chem. B. 2017, 5 (24), 4574–4578. 
(13) Teti, G.; Focaroli, S.; Salvatore, V.; Mazzotti, E.; Ingra, L.; Mazzotti, A.; Falconi, M., 
The Hypoxia-Mimetic Agent Cobalt Chloride Differently Affects Human Mesenchymal Stem 
Cells in Their Chondrogenic Potential. Stem Cells Int. 2018, 2018, 3237253. 
(14) Ghosh, C.; Manjunath, G. B.; Akkapeddi, P.; Yarlagadda, V.; Hoque, J.; Uppu, D. S. S. 
M.; Konai, M. M.; Haldar, J., Small Molecular Antibacterial Peptoid Mimics: The Simpler the 
Better! J. Med. Chem. 2014, 57 (4), 1428–1436. 
(15) Kohn, E. M.; Shirley, D. J.; Arotsky, L.; Picciano, A. M.; Ridgway, Z.; Urban, M. W.; 
Carone, B. R.; Caputo, G. A., Role of Cationic Side Chains in the Antimicrobial Activity of 
C18G. Molecules 2018, 23 (2), 329. 
(16) Bradshaw, J. P., Cationic antimicrobial peptides - Issues for potential clinical use. 
Biodrugs 2003, 17 (4) 233–240. 
(17) Tennessen, J. A., Molecular evolution of animal antimicrobial peptides: widespread 
moderate positive selection. J. Evol. Biol. 2005, 18 (6), 1387–1394. 
(18) Grinda, M.; Clarhaut, J.; Renoux, B.; Tranoy-Opalinski, I.; Papot, S., A self-immolative 
dendritic glucuronide prodrug of doxorubicin. MedChemComm 2012, 3 (1), 68–70. 
(19) Liang, D.; Wu, X.; Hasinoff, B. B.; Herbert, D. E.; Tranmer, G. K., Evaluation of 
Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia 
Targeting Prodrugs. Molecules 2018, 23 (8), 2041. 
(20) Mauger, A. B.; Burke, P. J.; Somani, H. H.; Friedlos, F.; Knox, R. J., Self-Immolative 
Prodrugs: Candidates for Antibody-Directed Enzyme Prodrug Therapy in Conjunction with a 
Nitroreductase Enzyme. J. Med. Chem. 1994, 37 (21), 3452–3458. 
(21) Xiao, W.; Sun, G.; Fan, T.; Liu, J.; Zhang, N.; Zhao, L.; Zhong, R., Reductive Activity 
and Mechanism of Hypoxia- Targeted AGT Inhibitors: An Experimental and Theoretical 
Investigation. Int. J. Mol. Sci. 2019, 20 (24), 6308. 
135 | P a g e  
  
(22) O'Connor, L. J.; Cazares-Körner, C.; Saha, J.; Evans, C. N. G.; Stratford, M. R. L.; 
Hammond, E. M.; Conway, S. J., Efficient synthesis of 2-nitroimidazole derivatives and the 
bioreductive clinical candidate Evofosfamide (TH-302). Org. Chem. Front. 2015, 2 (9), 1026–
1029. 
(23) Wang, J.; Guise, C. P.; Dachs, G. U.; Phung, Y.; Hsu, A.; Lambie, N. K.; Patterson, A. 
V.; Wilson, W. R., Identification of one-electron reductases that activate both the hypoxia 
prodrug SN30000 and diagnostic probe EF5. Biochem. Pharmacol. 2014, 91 (4), 436–446. 
(24) Zhang, X. F., The effect of phenyl substitution on the fluorescence characteristics of 
fluorescein derivatives via intramolecular photoinduced electron transfer. Photochem. 
Photobiol. Sci. 2010, 9, 1261–1268. 
(25) Yeoh, Y. Q.; Yu, J.; Polyak, S. W.; Horsley, J. R.; Abell, A. D., Photopharmacological 
control of cyclic antimicrobial peptides. ChemBioChem 2018, 19 (24), 2591–2597. 
  
136 | P a g e  
  
4.7 Supplementary Information 
4.7.1 Materials 
Dichloromethane (CH2Cl2), N,N‐dimethylformamide (DMF), diethyl ether, ethyl acetate, and 
methanol (MeOH) were purchased from Merck, Australia. 4-nitrobenzyl chloroformate, 10-
chloro-9-anthraldehyde, octylamine, sodium borohydride, dioxane, trifluoroacetic acid (TFA), 
and diisopropylethylamine (DIPEA) were purchased from Sigma–Aldrich, Australia. Sodium 
carbonate (Na2CO3), sodium chloride (NaCl), tin(II) chloride (SnCl2.2H2O), potassium 
hydrogen sulphate (KHSO4), magnesium sulphate (MgSO4), hexane, and dimethylsulfoxide 
(DMSO) were purchased from Chem Supply, Australia. o-(Benzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluorophosphate (HBTU), H-Lys-OH.HCl, and Boc-Lys(Boc)-OH, 
were purchased from Chem-Impex International, Inc., USA. Sodium azide and acetonitrile were 
purchased from Thermo Fisher Scientific, Inc., Australia. Chloroform (CHCl3), and 
hydrochloric acid (HCl) were purchased from RCI Labscan, Ltd., Australia. All solvents and 
reagents were used without purification unless noted. 
4.7.2 Methods 
Reverse Phase High Performance Liquid Chromatography (RP-HPLC) 
All samples were analyzed by reverse phase high performance liquid chromatography (RP-
HPLC), using a HP 1100 LC system equipped with a UV-Vis absorbance detector and a 
Phenomenex Analytical C18 column (Discovery BIO Wide Pore C5-5, 250 x 10 mm, 5 μm). 
Aqueous solvent A: Water:TFA (100:0.1 v/v) and organic solvent B: ACN:TFA (100:0.08 v/v) 
were used.  
Purification of the samples were performed by RP-HPLC using a Gilson purification system 
equipped with a UV-Vis absorbance detector and a Supelco Analytical C18 column (Discovery 
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BIO Wide Pore C5-5, 250 x 10 mm, 5 μm). Aqueous solvent A: Water:TFA (100:0.1 v/v) and 
organic solvent B: ACN:TFA (100:0.08 v/v) were used during the purification process. 
Absorbance Measurements 
The absorbance spectra were obtained at 25 ± 0.5°C on the BioTek™ Synergy™ H4 hybrid 
microplate reader. All measurements were performed in a 96-well plate with a concentration of 
approximately 100 μg/mL of all samples in DMSO. The absorbances for all samples were 
measured between 200-800 nm. 
Fluorescence Measurements 
The fluorescence spectra were obtained at 25 ± 0.5°C on the BioTek™ Synergy™ H4 hybrid 
microplate reader. All measurements were performed in a 96-well plate with a concentration of 
approximately 100 μg/mL of all samples in DMSO. The maximum absorbance wavelength, λmax 
(380 nm) was used as the excitation wavelength for all fluorescence measurements, while the 
emission wavelength was set at 400-600 nm. The average of the triplicates was calculated to 
obtain the average emission intensity for each sample. 
Antibacterial Susceptibility Evaluation 
Antibacterial activity was determined by the microdilution broth method as recommended by 
the CLSI (Clinical and Laboratory Standards Institute, Document M07-A8, 2009, Wayne, Pa.) 
using cation-adjusted Mueller-Hinton broth (Trek Diagnostics Systems, U.K.). Serial two-fold 
dilutions of each sample were made using DMSO as the diluent. Trays were inoculated with 5 
x 104 CFU of either S. aureus ATCC 49975 or E. coli K 12 in a volume of 100 μL (final 
concentration of DMSO was 3.2% (v/v)), and incubated at 37°C for 16-20 hours. Growth of the 
bacterium was quantified by measuring the absorbance at 620 nm.  
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4.7.3 Experimental 
4.7.3.1 Synthesis of N2,N6-bis(((4-nitrobenzyl)oxy)carbonyl)lysine (4) 
 
To a stirring solution of 4-nitrobenzyl chloroformate (4.0 g, 18.6 mmol) in dioxane (15 mL), a 
solution of sodium azide (1.4 g, 21.5 mmol) in water (5 mL) was added dropwise, and the 
mixture was stirred for 2h at rt. This solution was added dropwise to a stirring solution of H-
Lys-OH.HCl (1.7 g, 9.3 mmol) in 1:1 dioxane/10% Na2CO3 (10 mL). The resulting mixture was 
maintained between pH 9-10 with the addition of 10% Na2CO3 and stirred overnight at rt. Water 
(50 mL) was added to the mixture and the suspension was washed with diethyl ether (3 x 50 
mL). The aqueous layer was acidified with 1M HCl, and the precipitate was filtered and dried 
under suction to give a white solid (2.5 g, 53%). 1H NMR (500 MHz, DMSO-d6): δ 8.23 (d, 
J=8.7 Hz, 4H), 7.61-7.57 (m, 5H), 7.39 (t, J=5.4 Hz, 1H), 5.18 (d, J=13.1 Hz, 4H), 3.92-3.87 
(m, 1H), 3.01-2.97 (m, 2H), 1.74-1.67 (m, 1H), 1.63-1.55 (m, 1H), 1.44-1.37 (m, 2H), 1.36-1.30 
(m, 2H). m/zcalc: 505.1565, m/zfound: 505.1580 [M+H]
+.  
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4.7.3.2 Synthesis of N-((10-chloroanthracen-9-yl)methyl)octan-1-aminium (3) 
 
To a stirring solution of 10-chloro-9-anthraldehyde (2.0 g, 8.3 mmol) in 1:1 dry chloroform/dry 
methanol (80 mL), octylamine (1.07 g, 8.3 mmol) was added dropwise, and the mixture was 
stirred for 6h at rt. The resulting mixture was cooled to 0 °C before the addition of sodium 
borohydride (0.57 g, 15.0 mmol), and the mixture was warmed to rt with stirring overnight. The 
solvent was removed in vacuo, and the residue was dissolved in diethyl ether (60 mL). 2N NaOH 
(60 mL) was added, and the mixture was stirred vigorously for 15 mins at rt. The immiscible 
fractions were separated, and the organic layer was washed with water (2 x 80 mL) and brine (2 
x 80 mL). The organic layer was dried over MgSO4, and the solvent was removed in vacuo. 4N 
HCl (12 mL) was added to the residue, resulting in an instantaneous formation of a precipitate. 
The precipitate was filtered under suction and washed with hexane to give a yellow solid (2.2 g, 
76%). 1H NMR (500 MHz, CDCl3): δ 9.99 (br s, 2H), 8.52 (d, J=8.7 Hz, 2H), 8.40 (d, J=8.9 Hz, 
2H), 7.72-7.69 (m, 2H), 7.63-7.60 (m, 2H), 4.95 (br s, 2H), 2.64-2.58 (m, 2H), 1.77-1.71 (m, 
2H), 1.18-1.09 (m, 10 H), 0.79 (t, J=7.1 Hz, 3H). m/zcalc: 354.1983, m/zfound: 354.1981 [M+H]
+.  
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4.7.3.3 Synthesis of the antibacterial prodrug (2) 
 
To a solution of N2,N6-bis(((4-nitrobenzyl)oxy)carbonyl)lysine (1.3 g, 2.6 mmol) in 5:2 
DMF/chloroform (30 mL), DIPEA (0.8 g, 6.4 mmol) and HATU (1.0 g, 2.6 mmol) were added 
and stirred for 10 mins at 0 °C. N-((10-chloroanthracen-9-yl)methyl)octan-1-aminium (0.9 g, 
2.6 mmol) was added to the mixture and stirred for 30 mins at 0 °C. The mixture was warmed 
to rt and stirred overnight under N2. The solvent was removed in vacuo and the residue was 
dissolved in ethyl acetate (60 mL). The solution was washed with KHSO4 (60 mL), water (3 x 
60 mL) and brine (60 mL), and the organic layer was dried over MgSO4. The solvent was 
removed in vacuo and the crude product was purified by RP-HPLC to give a yellow solid. 1H 
NMR (500 MHz, CDCl3): δ 8.62 (d, J=8.1 Hz, 2H), 8.28 (d, J=8.8 Hz, 2H), 8.21-8.16 (m, 4H), 
7.63-7.60 (m, 2H), 7.58-7.55 (m, 2H), 7.50 (d, J=8.4 Hz, 2H), 7.46 (d, J=8.5 Hz, 2H), 6.11 (d, 
J=15.3 Hz, 1H), 5.89 (d, J=8.7 Hz, 1H), 5.30-5.27 (m, 1H), 5.19-5.13 (m, 4H), 4.81 (t, J=6.0 
Hz, 1H), 4.63-4.58 (m, 1H), 3.12-3.09 (m, 2H), 2.96-2.89 (m, 1H), 2.73-2.67 (m, 1H), 1.66-1.62 
(m, 2H), 1.50-1.33 (m, 6H), 1.21-1.15 (m, 2H), 1.11-1.03 (m, 4H), 0.97-0.93 (m, 3H), 0.91-0.88 
(m, 1H), 0.83 (t, J=7.3 Hz, 3H). m/zcalc: 840.3370, m/zfound: 840.3379 [M+H]
+.  
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4.7.3.4 Reduction of antibacterial prodrug (2) to give the active antibacterial 
(1) 
 
To a stirring solution of the prodrug (0.3 g, 0.4 mmol) in dry chloroform (30 mL) and dry 
methanol (10 mL), SnCl2.2H2O (1.35 g, 6.0 mmol) was added, and the mixture was refluxed at 
50 °C for 22h. The solvent was removed in vacuo and the residue was dissolved in chloroform 
(100 mL). The precipitate was filtered under suction, and the filtrate was washed with brine (4 
x 100 mL). The organic layer was dried over MgSO4, and purified by RP-HPLC to give a yellow 
solid. 1H NMR (500 MHz, CD3OD): δ 8.63 (d, J=8.5 Hz, 2H), 8.45 (d, J=8.7 Hz, 2H), 7.72-
7.65 (m, 4H), 6.16 (d, J=15.3 Hz, 1H), 5.50 (d, J=15.3 Hz, 1H), 4.29 (t, J=6.2 Hz, 1H), 3.05-
2.98 (m, 1H), 2.76-2.73 (m, 2H), 2.70-2.63 (m, 1H), 1.87-1.78 (m, 2H), 1.60-1.53 (m, 2H), 1.50-
1.40 (m, 2H), 1.39-1.30 (m, 2H), 1.24-1.17 (m, 2H), 1.11-1.05 (m, 2H), 1.02-0.96 (m, 3H), 0.94-
0.90 (m, 2H), 0.86 (t, J=7.3 Hz, 3H), 0.82-0.78 (m, 1H). m/zcalc: 482.2933, m/zfound: 482.2931 
[M+H]+.  
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4.7.4 Spectroscopic Analysis 
All samples were dissolved in DMSO at a concentration of 100 µg/mL, and the absorbance 
spectra were recorded using a BioTek™ Synergy™ H4 hybrid multimode microplate reader. 
 
Figure S4.1. Absorbance spectra for the prodrug 2 (blue) and active antibacterial 1 (green). The 
maximum absorbance wavelength (λmax) for both samples were determined to be 380 nm. 
  















143 | P a g e  
  




Figure S4.2. HPLC chromatograms of the samples visualized at 254 nm. (a) prodrug 2 and (b) active 
antibacterial 1. The active antibacterial 1 showed a retention time of 25 mins, while the prodrug 2 showed 
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4.7.6 1H NMR Spectra 
 
Figure S4.3. 1H NMR spectrum for N2,N6-bis(((4-nitrobenzyl)oxy)carbonyl)lysine (4) in DMSO-d6. 
 
Figure S4.4. COSY spectrum for N2,N6-bis(((4-nitrobenzyl)oxy)carbonyl)lysine (4) in DMSO-d6. 
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Figure S4.5. 1H NMR spectrum for N-((10-chloroanthracen-9-yl)methyl)octan-1-aminium (3) in CDCl3. 
 
Figure S4.6. COSY spectrum for N-((10-chloroanthracen-9-yl)methyl)octan-1-aminium (3) in CDCl3. 
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Figure S4.7. 1H NMR spectrum for the antibacterial prodrug 2 in CDCl3. 
 
Figure S4.8. COSY spectrum for the antibacterial prodrug 2 in CDCl3. 
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Figure S4.9. 1H NMR spectrum for the active antibacterial 1 afforded from the reduction of prodrug 2 
in CD3OD. 
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Foreword 
Previous chapters have focused on peptides containing a well-defined β-sheet secondary 
structure. This chapter looks at one of those photoswitchable peptides, namely 2a from Chapter 
2, hereafter referred to as peptide 1, to investigate the relationship between structure and 
function. To understand how a protein function necessitates a comprehensive study of their 
inherent structural dynamic properties. A single-peptide junction device was constructed for this 
purpose, characterized by electrical conductance to probe the structural dynamic behavior of the 
photoswitchable peptide. The peptide contains an azobenzene photoswitch to interconvert 
between the cis and trans isomer upon irradiation using light of a specific wavelength, which 
induces distinct structural dynamic behavior for each isomer. Real-time conductance 
measurements were performed on each isomer, with molecular dynamics simulations and 
quantum transport calculations conducted to rationalize the associated structural dynamic 
properties corresponding to each conductance state. Modulating the conductance within each 
isomer of peptide 1 revealed structural dynamic behavior that may potentially extend to both 
intrinsically disordered proteins, and those containing a well-defined secondary structure.  
 
Figure 5.0. A single-molecule junction containing a single-peptide with an azobenzene photoswitch to 
interconvert between the trans (left) and cis (right) configurations upon photoisomerization using UV 
and visible light. Real-time electrical measurements revealed multi-modal conductance states within 
each isomer, providing insights into the structural dynamics, and demonstrated the capacity to modulate 
conductance for bio-inspired electronic nanodevices.  
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5.1 Abstract 
Proteins are in continuous motion, with their structural dynamic behavior crucial to function. 
However, the majority of protein structures have been elucidated under equilibrium conditions. 
We aim to provide a better understanding of the dynamic behavior inherent to proteins by 
fabricating a label-free nanodevice comprising a single-peptide junction, to measure real-time 
conductance from which their structural dynamic behavior can be inferred. This device contains 
an azobenzene photoswitch for interconversion between a well-defined cis, and disordered trans 
isomer. Real-time conductance measurements revealed three distinct states for each isomer, 
with molecular dynamics simulations showing each state corresponds to a specific range of 
hydrogen bond lengths within the cis isomer, and specific dihedral angles in the trans isomer. 
We have provided hitherto undisclosed insights into the structural dynamic behavior of peptides, 
which may rationally extend to proteins, and demonstrated the capacity to modulate 
conductance, which advances the design and development of bio-inspired electronic 
nanodevices. 
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5.2 Introduction 
All proteins are dynamic structures that are in continuous motion,1 with atoms undergoing 
random thermal fluctuations and small conformational changes by virtue of their local 
environment.2 In the majority of cases, their function is determined by well-defined secondary 
structures,3 such as helices and β-strands, but in a growing number of cases, cellular function 
has been shown to be defined by a disordered structure.4 The functional role of such intrinsically 
disordered proteins is acknowledged in areas such as transcriptional regulation, translation, and 
cellular signal transduction, where flexibility is required for such transient interactions,5 
however our understanding of their structural dynamic properties is limited.6 These dynamic 
properties cannot be fully elucidated under equilibrium conditions,7 e.g. X-ray crystallography, 
that only provide a snapshot of the proteins frozen in crystal structures.8 To further our 
understanding of structured/unstructured proteins in motion, a sophisticated system is required 
to measure the physical properties from which their structural dynamic behavior can be inferred. 
This can be achieved using a functional, ultrasensitive device able to utilize simpler model 
peptides,9-10 with structural dynamic properties detected and measured in real-time with single-
bond resolution. Model peptides present as ideal alternatives for this purpose due to the intrinsic 
complexity of proteins.11  
Hence, we propose to exploit a single-peptide with an in-built photoswitch (cyclic peptide 1, 
Figure 5.1a) that allows reversible interconversion between two isomers to define their 
structural dynamic properties. We have previously shown that photoisomerization of this 
peptide triggers a significant geometric change between the well-defined cis isomer and 
disordered trans isomer.12 By having both isomers in the one simple model, it is possible to 
study their respective structural dynamic behavior in a controlled setting at the most 
fundamental level, which provides an appropriate model for the two protein structures described 
above. For device fabrication, cyclic peptide 1 will be covalently attached to nanogapped 
graphene electrodes to form a graphene-molecule-graphene single-molecule junction (GMG-
SMJ, Figure 5.1b). According to our established procedures,13-16 the single-molecule electronic 
detection method (e.g. field-effect transistor, FET) can then be used to probe the structural 
dynamic properties of each isomer of the peptide by transducing molecular information into 
quantized changes in conductance, with precise spatial control and high temporal resolution.17 
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This label-free technique is ideal for investigating the structural dynamic behavior of such a 
photoswitchable peptide, where alternative optical and mechanical detection methods can 
themselves induce undesirable structural changes within the molecule.18-19 When cyclic peptide 
1 is bridged between the nanogapped electrodes, photoisomerization of the azobenzene 
photoswitch is expected to result in a significant difference in electronic conductance between 
the two isomers due to their distinctive structures. Real-time conductance measurements on the 
GMG-SMJ platform enable the structural dynamic behavior of both well-defined and 
intrinsically disordered peptides to be revealed and compared from within the one single-peptide, 
thus providing important fundamental insights into this dynamic phenomenon. 
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5.3 Results and Discussion 
5.3.1 Peptide Design and Device Fabrication 
We have previously reported the synthesis of cyclic peptide 1 (Figure 5.1a).12 1H NMR 
spectroscopy and lowest energy density functional theory (DFT) calculations revealed the cis 
isomer of 1 adopts a β-sheet geometry with well-defined intramolecular hydrogen bonds, while 
the trans isomer is devoid of secondary structure.12 Detailed GMG-SMJ device fabrication and 
peptide coupling procedures are provided in the Supplementary Information. Briefly, the free 
amines located on the two ornithine residues of cyclic peptide 1 were coupled to the carboxylic 
acid-functionalized nanogapped graphene point contacts (Figure 5.1b). The fixed gap device 
has significant advantages over conventional STM measurements,20 particularly as the peptide 
forms stable, covalent linkages to the two electrodes. This device was then characterized 
electronically, where the successful formation of a single-molecule junction is confirmed by a 
typical I-V curve, and an open circuit represents no peptide coupling (Figure 5.1c). The real-
time measurements were carried out with a fixed source-drain bias voltage of 0.2 V and a 
sampling rate of 57.6 kSa/s at room temperature under ambient conditions. The photoinduced 
folding and unfolding processes in an azobenzene-containing peptide are well known21-22 and 
occur on a picosecond timescale,23 and thus are not the focus of this study.  
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Figure 5.1. A graphene-molecule-graphene single-molecule junction (GMG-SMJ) containing a 
photoswitchable peptide. (a) Chemical structures of the cis (left) and trans (right) isomers of cyclic 
peptide 1 upon photoisomerization using light of a specific wavelength. The azobenzene photoswitch is 
highlighted in red. (b) Schematic representation of GMG-SMJ device. (c) Molecular connection test. 
Comparison of I-V curves for an open circuit (no connection, black) and molecular connection (purple), 
indicating the successful formation of the GMG-SMJ device. 
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5.3.2 Real-time conductance measurements for cis and trans 
isomers of cyclic peptide 1 
To investigate the structural dynamics of cyclic peptide 1, real-time conductance measurements 
were initially undertaken on the GMG-SMJ containing the trans isomer under dark conditions 
(Figure 5.2, trans 1). Within this conformation, a trimodal distribution was found, where the 
observed current fluctuated between three distinct states, as shown in Figures 5.3 and S5.4. A 
low conductance state (State 1) was found to be the most populated, while States 2 and 3 
appeared like current spikes with moderate and high conductance, respectively. The resulting 
current-count histogram showed three Gaussian-type fitting peaks with occupancy rates of 90.9% 
± 0.5%, 7.4% ± 0.4%, and 1.7% ± 0.6%, corresponding to States 1, 2, and 3, respectively, 
indicating that State 1 is dominant in the trans isomer (Figure 5.3a). Figure S5.6d clearly shows 
that the noise level emanating from the device itself was approximately 1 nA, however, the 
difference in current between each of the three conductance states was shown to be in the order 
of 10 nA. This is highlighted in Figure S5.4, which shows all three conductance states observed 
over different time periods. Hence, the lower occupancy rates for State 2 and State 3 for the 
trans isomer are not deemed to be random noise, as the observed current values can clearly be 
discriminated from the noise. Dwell times (τ) of each state were extracted using a hidden 
Markov model (Figure S5.7) with time intervals obtained from QuB software,24 while the 
subsequent frequency analysis demonstrated typical single exponential functions. The 
corresponding dwell times of the low (τstate 1), moderate (τstate 2) and high (τstate 3) conductance 
states were 1.813 ± 0.083 ms, 0.073 ± 0.012 ms, and 0.094 ± 0.008 ms, respectively (Figure 
5.3c). These data indicate that the trans isomer undergoes thermal fluctuations, resulting in these 
distinct variations in conductance.   
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Figure 5.2. Real-time conductance measurements in a photoswitching cycle. Left: GMG-SMJ 
containing cyclic peptide 1 in its trans configuration (dark, trans 1), center: following UV irradiation 
(365 nm) to convert to the cis configuration (UV, cis), right: following Vis irradiation (420 nm) to 
convert to the trans configuration (Vis, trans 2). Insets: enlarged sections containing the relevant I-t 
curves upon UV irradiation (left, purple) and Vis irradiation (right, blue), showing instantaneous 
switching between isomers. VD = 0.2 V, VG = 0 V, and the sampling rate is 57.6 kSa/s. 
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Figure 5.3. Real-time conductance measurements of GMG-SMJ (trans 1) under dark conditions with 
corresponding statistical analyses. (a) Representative I-t trajectories of the GMG-SMJ (trans 1) (left) 
with the corresponding histogram (right). Three conductance states are observed in the I-t trajectories. 
The analysis of the current-count histogram shows the highest occupancy rate for low conductance state 
(State 1, blue), then moderate conductance state (State 2, orange), and high conductance state (State 3, 
red). Inset: enlarged section for States 2 and 3. (b) Enlarged section of 5.3a showing conductance states 
1-3. (c) Plots of time intervals for the low (left), moderate (center) and high (right) conductance states. 
Dwell times (τ) were extracted from the idealized fittings of I-t curves using QuB software as shown in 
the Supplementary Information (5.7.5 Kinetic analysis).   
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Upon irradiation using UV light (365 nm), the overall conductance increased instantaneously, 
indicating conversion to the cis isomer (Figure 5.2, purple inset). Detailed analysis of this 
dynamic process revealed that the real-time I-t measurements for the cis conformation also 
exhibited a trimodal current distribution, with occupancy rates of 14.3% ± 0.6%, 79.5% ± 0.7%, 
and 6.1% ± 2.4% for the low, moderate, and high states, respectively (Figure 5.4). In contrast 
to the trans isomer, the most populated state in the cis isomer is the moderate conductance state 
(State 2). The dwell times of the three states were calculated to be τstate 1 0.883 ± 0.061 ms, τstate 
2 1.067 ± 0.086 ms, and τstate 3 0.063 ± 0.002 ms corresponding to the low, moderate and high 
conductance states, respectively (Figure 5.4c). The overall conductance, occupancy rates and 
dwell times found for the cis isomer are not comparable to those of the GMG-SMJ containing 
the trans isomer, indicating that these three conductance states are clearly not a consequence of 
photoconversion between the isomers. As the dwell times for each state were observed to occur 
on a submillisecond timescale, and photoisomerization of azobenzene is known to occur on a 
picosecond timescale,25 the conductance changes could not solely originate from the azobenzene 
photoswitch. In addition, to demonstrate the reversible nature of the photoswitchable device, 
visible light (420 nm) was used to convert the peptide to the trans isomer (Figure 5.2, trans 2, 
blue inset). The conductance decreased instantaneously and essentially matched that of trans 1 
(Figure S5.5). Covalent binding to the graphene electrodes did not appear to greatly affect the 
intrinsic properties of cyclic peptide 1, with Figure S5.3 showing the ultrasensitive 
photoresponsive features that allow it to act as a light-triggered switch element. In support of 
the current fluctuations emanating from the photoresponse of the cyclic peptide and not from 
the graphene electrodes or the environment, control experiments on partially cleaved and totally 
cleaved graphene devices were carried out (Figure S5.6). Each control experiment exhibited 
only one Gaussian-type fitting peak for UV, visible light, and in dark conditions. The absence 
of current fluctuations from these controls indicates that UV/Vis light has no observable effect 
on the graphene device, and hence, does not influence our results. Overall, the high temporal 
resolution of real-time measurements demonstrates the presence of small structural 
perturbations within each conformation of cyclic peptide 1. These perturbations within each 
isomer may result from a negligible free energy barrier or the absence thereof, brought about by 
subtle movement of the peptide backbone,26 and could provide vital information on their 
structural dynamics. Furthermore, the increase in conductance following UV irradiation is 
attributed to the distinctive β-sheet secondary structure of the cis isomer, which is stabilized by 
intramolecular hydrogen bonds. In our previous study,27 it was reported that the formation and 
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deformation of hydrogen bonds occur on a submillisecond timescale in GMG-SMJs. As we 
observed the conductance to fluctuate between the three states of the cis GMG-SMJ on a 
submillisecond timescale (Figure 5.4), we postulate they are a direct consequence of the 
dynamic structural fluctuations that affect intramolecular hydrogen bonding. However, detailed 
computational studies are required to support these notions, and will be discussed in the 
following section.   
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Figure 5.4. Real-time conductance measurements of GMG-SMJ (cis) under UV conditions with 
corresponding statistical analyses. (a) Representative I-t trajectories of the GMG-SMJ (cis) (left) with 
the corresponding histogram (right). Three conductance states are observed in the I-t trajectories. The 
analysis of the current-count histogram shows the highest occupancy rate for the moderate conductance 
state (State 2, orange), then low conductance state (State 1, green), and high conductance state (State 3, 
grey). Inset: enlarged section for State 3. (b) Enlarged section of 5.4a showing conductance states 1-3. 
(c) Plots of time intervals for the low (left), moderate (center) and high (right) conductance states. Dwell 
times (τ) were extracted from the idealized fittings of I-t curves using QuB software as shown in the 
Supplementary Information (5.7.5 Kinetic analysis).  
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5.3.3 Molecular dynamics (MD) simulations of GMG-SMJ 
MD simulations were conducted to gain further insights into the observed structural dynamics 
of the GMG-SMJ. The representative snapshots of the cis and trans GMG-SMJs (Figure S5.10) 
during the course of simulations were chosen by the hieragglo algorithm-based cluster analysis 
using the root-mean-square (RMS) of the carbon atoms in the peptide backbone and azobenzene 
moiety. This was undertaken as the average frame derived from an MD run is commonly ill-
defined and does not represent an appropriate chemical structure. Quantum transport 
simulations using DFT in conjunction with non-equilibrium Green’s function (NEGF) were then 
performed to elucidate the difference in electronic conductance between these cis and trans 
GMG-SMJ snapshots. It was found that the cis GMG-SMJ possessed a zero-bias transmission 
coefficient of 3.0 × 10-12 Go at the Fermi level (red curve, Figure S5.10a), approximately two 
orders of magnitude higher than the trans GMG-SMJ (1.0 × 10-14 Go, black curve). Importantly, 
this trend is consistent with experimental observations (Figures 5.2 and S5.3). It is worth 
mentioning that we cannot make a direct comparison between the calculated transmission and 
the measured conductance, as coherent charge transport28-29 and electrodes of finite cross 
section30-31 were employed in the conductance calculations, while other incoherent processes32-
34 such as hopping may contribute to the conductance measurements. The Molecular Projected 
Self-consistent Hamiltonian (MPSH) states of the cis GMG-SMJ (Figure S5.12) exhibit a 
HOMO-LUMO energy gap of ~ 0.612 eV, while an increased HOMO-LUMO energy gap of ~ 
0.688 eV is given for the trans GMG-SMJ. Notably, the LUMO (Figure S5.12) in both GMG-
SMJs is localized on one of the electrodes, while the HOMO is distributed on the molecule, 
residing on the azobenzene moiety for the trans isomer, and the peptide backbone for the cis 
isomer. This indicates different roles for azobenzene and the peptide backbone in determining 
transmission conductance of the cis and trans isomers. Further transmission eigenchannel 
analysis for the cis GMG-SMJ showed a continuous and well-spanned electron density 
distribution across the entire junction (Figure S5.10b), indicating a higher conductance than its 
trans counterpart. The higher conductance in the cis GMG-SMJ is defined by the overlapping 
atomic orbitals from the peptide backbone, azobenzene moiety, and intramolecular hydrogen 
bonding (Figure S5.10b). In contrast, the trans GMG-SMJ exhibited a discontinuous conduction 
channel (Figure S5.10c), with the electron density predominantly localized on the azobenzene 
moiety, thus resulting in an overall lower conductance. This result, together with the frontier 
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MPSH states, indicates that the π-conjugated trans azobenzene plane plays a critical role in 
formulating the GMG-SMJ transmission eigenchannel (Figure S5.10c).  
Hence, the MD simulation for the trans GMG-SMJ was further analyzed by the cluster analysis 
method using the dihedral angle (φ) between the azobenzene and graphene planes. The dihedral 
angle is defined by six carbon atoms. Three of these were selected from the right-hand side 
electrode to determine the graphene plane, while the azobenzene plane is defined by the other 
three atoms; two from the moiety and one from the peptide/graphene contacting region indicated 
in Figures 5.5a-b. The corresponding histogram of dihedral angles is depicted in Figure 5.5c, 
and the representative snapshots for each cluster were subjected to quantum transport 
calculations. It was found that the computed conductance oscillated in a wave form following 
the change in the dihedral angle (Figure 5.5d). Clearly, three computed conductance states 
(States 1-3) were identified, which are consistent with the real-time experimental conductance 
measurements (Figure 5.3), where the trans isomer predominantly resides in the low 
conductance state (State 1), with a lower population evident for moderate and high conductance 
states. Specifically, the computed low conductance state (State 1, green dashed line, Figure 5.5d) 
spans a broad range of dihedral angles and has the highest occupancy rate of ~47.6% (Table 
S5.3), with φ ≈ 25° being the predominant species (green band, Figure 5.5c). The computed 
transmission eigenchannel for the selected device snapshot (State 1, Figure 5.5e) displays a 
discontinuous conduction channel with much lower electron density. The moderate conductance 
state (State 2, orange band, Figure 5.5c) was found at φ ≈ -50° and 40°, showing the second 
highest occupancy rate of ~28.6% (Table S5.3 and Figure 5.5f), while the high conductance 
state (State 3, blue dashed line) was found at φ ≈ 0°, with the lowest occupancy rate of ~23.8% 
(blue band, Figure 5.5c and Table S5.3). This dihedral angle (φ ≈ 0°) allows for a better π 
electron alignment between the trans azobenzene plane and graphene electrodes, thus promoting 
electronic coupling between the azobenzene and the electrodes. This is evidenced by the 
transmission eigenchannel (Figure 5.5g), which shows a well-spanned conductive channel with 
high electron density, predominantly localized on the azobenzene moiety. However, this 
conformation induces such a large distortion in each of the ornithine side chains, resulting in the 
lowest occupancy rate. The simulated conductance states and their corresponding occupancy 
rates concur with the real-time conductance measurements, providing clear theoretical evidence 
to interpret the experimental observations. Hence, these MD simulations revealed that φ is 
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crucial for modulating conductance within the three discrete states found in the trans GMG-
SMJ. While the occupancy rate is predominantly in the low conductance state for the trans 
isomer, MD simulations have shown that it can also experience higher conductance, depending 
on the specific orientation of the peptide within the GMG-SMJ. Notably, such variations in the 
dihedral angles amount to modulation of the conductance within each discrete state. The 
oscillation of conductance observed in Figure 5.5d suggests that the inherent flexibility of the 
trans isomer efficiently provides direct access to each conductance state over a wide and diverse 
range, depending on the orientation of the peptide. This structural dynamic behavior may 
potentially extend to intrinsically disordered proteins, where such structural plasticity may 
influence transient interactions that are readily broken and reformed, such as cellular signaling. 
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Figure 5.5. Conductance analyses for the trans GMG-SMJ MD simulation. (a) Top view and (b) side 
view of the dihedral angle (φ) between the azobenzene and graphene planes as defined by three atoms 
from each. (c) Histogram (curve) of dihedral angles over the course of MD simulation, and corresponding 
attribution (coloured bands) to the conductance states (green band = low conductance state, orange = 
moderate, blue = high). (d) Dependence of computed conductance on dihedral angles for the selected 
trans GMG-SMJ snapshots. (e–g) Computed eigenchannels of the selected GMG-SMJ snapshots with 
their respective dihedral angles indicated, representing the three conductance states. 
MD simulations showed that the cis isomer adopts a well-defined β-sheet secondary structure 
maintained by two intramolecular hydrogen bonds. Hydrogen bonding has been shown to play 
a significant role in electronic transport within peptides.35-36 There are three possible factors 
affecting the conductance in the cis GMG-SMJ as evidenced in Figure S5.10b, namely (i) 
dihedral angle (φ) between the azobenzene moiety and electrode plane, (ii) hydrogen bond 1 
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distance (d1), and (iii) hydrogen bond 2 distance (d2) (Figure 5.6a). Hydrogen bond d1 is defined 
by the CO (Leu) – NH (Orn) distance, while d2 is defined by the CO (Val) – NH (Azo) distance. 
The cis GMG-SMJ MD trajectory was further analyzed by the cluster analysis method utilizing 
these three factors. In order to investigate one factor in isolation from the other two variables, 
representative snapshots were chosen for one, while keeping the other two parameters relatively 
constant. The subsequent quantum transport simulations revealed that changes in either φ or d2 
do not lead to a noticeable change in the computed conductance of the cis GMG-SMJ (Figure 
S5.13), whereas d1 was found to be critical in determining conductance (Figure 5.6b). The 
computed conductance values are 4.5×10-11 Go and 4.4×10
-12 Go for d1 = 1.76 Å and 1.85 Å 
respectively, while a further drop in conductance to 10-13 Go was experienced when d1 is greater 
than 2.10 Å (Figure 5.6b). The three distinct conductance states representative of d1 shown in 
Figures 5.6d-f are: 1.76 Å (high), 1.85 Å (moderate), and 2.21 Å (low). It was determined that 
the moderate conductance state (State 2) with d1 between 1.80 – 2.10 Å was the predominant 
species (orange band, Figure 5.6c). Occupancy rates of ~28.4%, ~65.9%, and ~5.7% were found 
for the low, moderate, and high conductance state (States 1–3) respectively (Table S5.4 and 
Figure 5.6c), which also correspond with the experimental real-time measurements for the cis 
isomer (Figure 5.4). These three conductance states remarkably coincide with the fluctuations 
in d1 as revealed by MD, thus confirming that d1 is directly correlated to conductance. While 
the dihedral angle (φ) is crucial to the conductance in the trans isomer, virtually no change in 
conductance was found when φ is between -60 and 60 degrees in the cis isomer (Figure S5.13), 
suggesting that flexibility is not such a critical factor here. In contrast to the more flexible trans 
isomer, significant changes in conductance in the cis isomer can occur through the smallest of 
structural dynamic perturbations (sub-angstrom) within d1. Thus, the structural dynamic 
properties revealed in d1 provide new opportunities to modulate conductance within the well-
defined cis isomer.  
Despite the snapshot d1 = 2.21 Å representing a strong hydrogen bond,
37 it lies in the low 
conductance state (State 1). It is noteworthy that Figure 5.6b shows two additional data points, 
d1 = 2.60 Å (moderate hydrogen bond strength) and d1 = 3.80 Å (weak hydrogen bond strength), 
that are also located in the low conductance state. However, when d1 is less than 2.10 Å, the 
conductance increased exponentially to State 2 (moderate) and State 3 (high). These results may 
provide support for further investigation into the definition and interpretation of hydrogen bond 
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strengths within a well-defined secondary structure. Collectively, this work goes beyond 
transducing the hydrogen bond dynamic process into real-time electronic signals, and indeed 
correlates the hydrogen bond lengths with their associated conductance states. These structural 
dynamic properties observed within d1 of the cis isomer with single-bond resolution, provide 
crucial insights into the structural dynamic behavior of proteins that contain well-defined 
intramolecular hydrogen bonds needed to stabilize secondary structure.  
 
Figure 5.6. Conductance analyses for the cis GMG-SMJ MD simulation. (a) Image of hydrogen bond 1 
(d1) and hydrogen bond 2 (d2). (b) Dependence of computed conductance on d1 distance. (c) Histogram 
(curve) of d1 over the course of MD simulation, and corresponding attribution (coloured bands) to the 
conductance states. (d–f) Computed eigenchannels of the selected snapshots representing the low 
conductance state (State 1), moderate (State 2), and high (State 3).  
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5.4 Conclusion 
Conductance measurements on a GMG-SMJ containing the photoswitchable cyclic peptide 1 
revealed two distinct conformations, with an overall higher conductance observed in the cis 
isomer than for its trans counterpart, which is consistent with our MD simulations. This single-
molecule electronic device has established itself as a robust platform to unravel the structural 
dynamic properties of peptides at the molecular level. For the first time, we have unveiled three 
distinct conductance states which remarkably correlate to various unique structural dynamic 
properties within each isomer. Not only have we demonstrated modulation of conductance 
within this device using light, but also revealed that perturbations within both the well-defined 
and intrinsically disordered isomers of cyclic peptide 1 (structural dynamics) provide further 
capacity to manipulate conductance with precise spatial control and high temporal resolution. 
The trans isomer of cyclic peptide 1 was shown to possess a disordered configuration, while the 
cis isomer was found to contain a well-defined β-sheet secondary structure. Hence, by studying 
these two distinctly different isomers within the one single-peptide, we have been able to 
provide hitherto undisclosed fundamental insights into their unique structural dynamic behavior, 
which may rationally extend to both intrinsically disordered proteins and those containing a 
well-defined secondary structure. This capacity to modulate conductance within peptides paves 
the way for the future design of multi-modal nanodevices with practical applications in areas 
such as biosensing, where such bio-inspired molecular components offer a greener approach for 
the advancement of these technologies.   
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5.7 Supplementary Information 
5.7.1 Device fabrication and molecular connection 
The high-quality single-layered graphene was grown by chemical vapor deposition (CVD) on 
copper foils. The graphene films were then transferred onto the SiO2/Si wafers (300 nm silicon 
oxide) by wet etching. The source/drain metal electrode (8 nm Cr/60 nm Au) arrays were 
patterned by three steps of lithography and two steps of thermal evaporation. The nanogapped 
graphene electrode arrays were constructed by the electron beam lithography (EBL), followed 
by oxygen plasma etching to functionalize the graphene point contacts with carboxylic acid 
groups (Figure S5.1). For the molecular linkage, the cyclic peptide (1.0 mg, 0.98 µmol) was 
coupled onto the carboxylic acid groups on the graphene point contacts via amide bond using 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) (10 mg, 52 µmol), a well-known 
carbodiimide dehydrating/activating agent, in pyridine (10 mL) for 48h in the dark. After 
reaction, the device was removed from the solution, rinsed with deionized water and acetone 
for several times, and dried under a N2 stream.  
 
Figure S5.1. Schematic diagram for the device fabrication procedure.  
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5.7.2 Probability analysis of single-molecule connection 
A theoretical analysis was performed to predict the number of junctions contributing to the 
charge transport, as shown in previous studies.1-2 The probability of connected devices with n-
rejoined junctions, Gn was calculated using a binomial distribution as shown in (1) and 
optimized connection yields, Yconnection as shown in (2): 
 
where m is the number of graphene contacts (169 in current pattern) and p is the probability of 
successful connection for each junction.  
The device is conductive if there are one or more molecules connected to the junction. Peptide 
coupling to the nanogapped point contacts under optimized conditions yielded successful 
connection rate of ~2%, which meant that G0 was 0.98. Thus, the ratio of single-molecule 
junction devices to the overall reconnected devices was expressed as G1/2%, which was 
estimated to be 98.99%. This indicated that there was only one molecule in the junction that 
contributed to the conductivity in most cases. 
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5.7.3 Experimental Results 
5.7.3.1 Electrical measurements of single-molecule junctions 
I-V measurements were carried out by utilizing an Agilent 4155C semiconductor 
characterization system with a scanning interval of 0.05 V per step. The real-time measurements 
of the device were carried out by a Karl Suss (PM5) manual probe station. The electrical signals 
were collected and exhibited by an HF2LI Lock-In Amplifier, a DL 1211 Current Amplifier, 
and a NIDAQ card, with a sampling rate of 57.6kSa/s and a bias voltage of 0.2 V. Each 
measurement was performed at room temperature under ambient conditions. The test system 
was equipped with an electric shield to ensure that any possible external disturbance would not 
affect the conductance properties of the device. 
 
Figure S5.2. I-V curves of four different graphene-molecule-graphene single-molecule junctions (GMG-
SMJs). The gate voltage was 0 V.  
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5.7.3.2 Reproducibility of the photoswitching process in single-molecule 
junctions 
 
Figure S5.3. Conductance measurements of the photoswitching process of single-molecule junctions at 
different bias voltages, demonstrating the reproducibility of the photoswitching process. (a) VD = 0.1 V, 
(b) VD = –0.1 V, (c) VD = 0.2 V, (d) VD = –0.2 V. The gate voltage was 0 V. Measurements were carried 
out using Agilent 4155C semiconductor characterization system with a lower sampling rate of 2 ms.  
179 | P a g e  
  
5.7.3.3 Real-time electrical measurements of GMG-SMJs at different time 
periods 
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Figure S5.4. Real-time conductance measurements of GMG-SMJs at different time periods. Figures a-
d show another set of data from the same device in Figure 5.3. (a) I-t curves under dark condition, where 
States 1-2 were observed, (b) I-t curves under dark condition, where all three states (States 1-3) were 
observed, (c) I-t curves under UV condition, where all three states (States1-3) were observed, (d) I-t 
curves under UV condition, where States 2-3 were observed. VD = 0.2 V.  
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Figure S5.5. Real-time conductance measurements of cyclic peptide 1 under visible light irradiation 
after UV exposure.  
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5.7.4 Electrical measurements of control experiments 
 
Figure S5.6. Control experiments under different conditions. (a-c) I-t curves of a partially cleaved 
graphene ribbon device under dark conditions, UV, and visible light, respectively. (d) I-t curves of a 
totally cleaved graphene ribbon device, showing the noise level that originates from the equipment and 
the environment. VD = 0.2 V. 
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5.7.5 Kinetic Analysis 
Dwell times (τ) were extracted from the idealized fittings of the original I-t curves through the 
QuB software (Figure S5.7). Three states were distinguished for each isomer. In general, an 
elementary single-molecule reaction follows a single-step Poisson process that is stochastic, 
memory-free, and independent. Thus, the distributions of the dwell times of events can be fitted 








where 〈𝜏〉  is the mean dwell time and can be calculated through the exponential fitting 
parameter. 
 
Figure S5.7. Kinetic analysis model. I-t curve (black) of the GMG-SMJ and the idealized fit (red) 
obtained from a segmental k-means method based on the hidden Markov model analysis using the QuB 
software. 
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5.7.6 Molecular Dynamics (MD) Simulations of GMG-SMJs 
5.7.6.1 GMG-SMJ junction model 
Each graphene electrode consists of 128 carbon atoms arranged in a 16  8 array (Figure S5.8). 
The contact point extends out from the middle edge, and is comprised of 11 carbon atoms 
(Figure S5.9b). The two electrodes are aligned in the same plane, with critical distances 
indicated in Figure S5.8. Cyclic peptide 1 in either of the two photoisomeric states was bridged 
between the nanogapped graphene electrodes via amide bonds. All inner edge carbon atoms 
were saturated with H atoms.  
 
Figure S5.8. GMG-SMJ junction model constructed for MD simulations, where brown spheres denote 
carbon, red = oxygen, silver = nitrogen, and pale pink = hydrogen. 
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5.7.6.2 Force field parameters 
The AMBER ff14SB and GAFF 2 force field parameters were adopted for all MD simulations. 
The partial atomic charges of ornithine (ORN) was derived by Pendley,3 and downloaded via 
the AMBER parameter database (http://research.bmh.manchester.ac.uk/bryce/amber/). The 
partial atomic charges of the azobenzene (AZO, Figure S5.9a) residue were determined with the 
restrained electrostatic potential (RESP) approach4 by fitting the electrostatic potential grids of 
both the trans and cis isomers using the RESP program implemented in the AMBER package. 
The derived partial atomic charges and their associated atom types are listed in Table S5.1, and 
the GAFF parameters are included in Table S5.2. In relation to the graphene electrodes (Figure 
S5.9b), the atoms in the shade region were set as a zero atomic charge, and fixed at a force 
constant of 500 kcal/mol/Å3. The partial atomic charges, types and GAFF parameters of the 
atoms situated in the peptide/electrode contacting region are included in Tables S5.1 and S5.2. 
 
Figure S5.9. (a) Chemical structure of the azobenzene residue adopted for the determination of partial 
atomic charges. (b) Graphene electrode and key atoms pertaining to the contacting region.   
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Table S5.1. Atom type and partial atomic charge adopted for the azobenzene residue and electrode atoms. 
Atom name Atom type Charge Atom name Atom type Charge 
Azobenzene      
N1 n -0.4157 N9 ne -0.3711 
H1 hn 0.2719 N10 nf -0.3008 
C2 c3 0.0024 C11 ca 0.6492 
H2 h1 0.0691 C12 ca -0.3691 
C3 ca 0.0241 H12 ha 0.1852 
C4 ca -0.1137 C13 ca -0.0808 
H4 ha 0.1743 H13 ha 0.1542 
C5 ca -0.4849 C14 ca -0.2258 
H5 ha 0.2193 H14 ha 0.1723 
C6 ca 0.7532 C15 ca 0.0537 
C7 ca -0.4849 C16 ca -0.4323 
H7 ha 0.2193 H16 ha 0.1718 
C8 ca -0.1137 C17 c 0.5973 
H8 ha 0.1743 O17 o -0.5679 
 
Electrode 
     
C19 c 0.5973 C23 ca 0.1034 
O19 o -0.5679 C24 ca -0.3798 
C20 ca 0.3412 H24 ha 0.1754 
C21 ca -0.3154 C25 ca -0.3459 
H21 ha 0.1654 H25 ha 0.1695 
C22 ca 0.0568    
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Table S5.2. GAFF parameters adopted for the azobenzene residue and electrode atoms. 
Bond kb (kcal/mol) Distance (Å) 
Azobenzene   
c3-hc 330.6 1.097 
c-c3 313.0 1.524 
c-o 637.7 1.218 
c-n 427.6 1.379 
hn-n 403.2 1.013 
c3-n 328.7 1.462 
c3-h1 330.6 1.097 
Electrode 
  
ca-ca 378.6 1.398 
ca-ha 395.7 1.086 
c-ca 272.7 1.491 
 
Angle kθ (kcal/mol/radian2) Degree (o) 
Azobenzene   
hc-c3-hc 39.40 107.58 
c-c3-hc 26.93 108.77 
c3-c-o 67.40 123.20 
c3-c-n 66.79 115.18 
c-n-hn 48.33 117.55 
c-n-c3 63.39 120.69 
n-c-o 74.22 123.05 
ca-c-n 67.68 115.25 
h1-c3-n 49.84 108.88 
c3-n-hn 45.80 117.68 
h1-c3-h1 39.24 108.46 
Electrode   
ca-ca-ca 68.8 120.02 
ca-ca-ha 48.7 119.88 
c -ca-ca 66.4 120.33 





Vn/2 (kcal/mol) Phase (o) Periodicity 
Azobenzene     
hc-c3-c-o 1 0.80 0.000 -1.000 
hc-c3-c-o 1 0.00 0.000 -2.000 
hc-c3-c-o 1 0.08 180.00 3.000 
n-c-c3-hc 6 0.00 180.00 2.000 
c3-c-n-hn 4 10 180.00 2.000 
c3-c-n-c3 1 0.00 0.00 -2.000 
c3-c-n-c3 1 1.50 180.00 1.000 
o-c-n-hn 1 2.50 180.00 -2.000 
o-c-n-hn 1 2.00 0.00 1.000 
o-c-n-c3 4 10.00 180.00 2.00 
h-n-c-ca 4 10.00 180.00 2.00 
c3-n-c-ca 4 10.00 180.00 2.00 
hc-c3-n-c 6 0.00 0.00 2.00 
hn-n-c-o 1 2.50 180.00 -2.00 
hn-n-c-o 1 2.00 0.00 1.00 
c3-n-c-o 4 10.00 180.00 2.00 
hc-c3-n-hn 6 0.00 0.00 2.00 
Electrode     
X -ca-ca-X 4 14.5 180.00 2.00 
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5.7.6.3 MD simulation protocols and data analysis 
MD simulations for the GMG-SMJ junctions were performed with the non-periodic condition 
in the canonical (NVT) ensemble using the Sander algorithm, as implemented in the Amber 
package (Ver 16-17.03).5 After energy minimization using the steepest descent (5000 steps) and 
conjugate gradient (5000 steps) method, each system was warmed up to room temperature (300 
K) in 20 ps, and then allowed to equilibrate for 500 ps. In the production runs, the MD trajectory 
was written for every 100 steps, resulting in 6×104 frames (6 ns) for the subsequent cluster 
analyses. The following settings were activated throughout the heating and production phases. 
The temperatures were maintained using the weak coupling algorithm (ntt = 1), with a time step 
of 1 fs. The SHAKE algorithm was used to constrain bonds involving hydrogen atoms. The 
cluster analyses were performed for the production trajectories using the CPPTRAJ software,6 
and the Chimera software7 was chosen to visualize MD snapshots. 
In order to correlate structural dynamics and conductance of the GMG-SMJ junctions, the MD 
trajectory for either of the two isomers was first subjected to the cluster analysis based on the 
root-mean-square (RMS) value of the carbon atoms in the azobenzene and peptide backbone 
using the hieragglo algorithm with an epsilon value of 2. The representative snapshots for each 
isomer were chosen to compute the transmission spectra (Figure S5.10), because the average 
frame derived from a MD run is commonly ill-defined and does not represent an appropriate 
chemical structure. Subsequently, the MD trajectory for the trans isomer was classified into 
eleven clusters based on the dihedral angle (Figure 5.5a) using the hieragglo algorithm with an 
epsilon value of 10. The corresponding histogram is depicted as a function of dihedral angle 
(Figure 5.5c), and the representative snapshots for each cluster were subjected to transport 
conductance calculations (Figure 5.5d). Similarly, the MD trajectory for the cis isomer was 
classified into eleven clusters based on either the dihedral angle (Figure 5.5a) or the two 
intramolecular hydrogen bonds (namely d1 and d2, Figure 5.6a) using the hieragglo algorithm 
with an epsilon value of 10. No definitive correlation of conductance was found with the 
dihedral angle or d2 (Figure S5.13). The corresponding histogram as a function of d1 is depicted 
in Figure 5.6c, and the representative snapshots for each cluster were subject to compute 
transport conductance (Figure 5.6b).  
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5.7.7 Computational Results 
5.7.7.1 Quantum transport calculations 
Transmission coefficients T(E) of each selected GMG-SMJ molecular junction snapshot were 
conducted with the non-equilibrium Green’s function approach combined with density 
functional theory (NEGF-DFT), as implemented in the TRANSIESTA package.8 The entire 
junction device was fitted into a cuboid box, with a space from the graphene plane to the bottom 
of 6.0 Å, and 24.0 Å to the top. The transport direction was defined as the z axis, with periodic 
boundary conditions employed in the xy directions. A GGA/PBE functional9 and norm-
conserving Troullier-Martins pseudopotentials10 were employed. The valence electronic orbitals 
of the cyclic peptide and the electrode contact points were described using double-ζ polarized 
(DZP) basis sets, while the single-zeta polarized (SZP) was chosen for the other C atoms in the 
electrodes. The Brillouin zone was sampled as a Monkhorst-Pack grid using 1 × 1 × 50 k-points 
and a cut-off energy of 250 Ry was used. Eigenchannels were computed using the Inelastica 
package,11 and visualized using the VESTA program.12  
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5.7.7.2 Transmission channels and eigenchannels 
 
Figure S5.10. Transmission spectra and eigenchannels of the representative cis and trans GMG-SMJ 
snapshots. (a) Zero-bias transmission spectra of the cis (red) and trans (black) GMG-SMJs. Transmission 
eigenchannels for (b) cis and (c) trans GMG-SMJs.  
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Figure S5.11. Transmission spectra of the representative three conductance states for (a) cis and (b) 
trans GMG-SMJ snapshots. 
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5.7.7.3 Molecular projected self-consistent Hamiltonian (MPSH) states of the 
trans and cis GMG-SMJs 
 
Figure S5.12. MPSH states of the highest occupied molecular orbitals (HOMOs) and lowest unoccupied 
molecular orbitals (LUMOs) for the cis (left) and trans (right) GMG-SMJs.  
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Table S5.3. Statistical analysis of the dihedral angle between azobenzene and electrode plane for the 
trans GMG-SMJ.  
Dihedral angle (°) Conductance state Occupancy rate (%) 
< -60 
State 1 47.6 
-40 to -5 
15 to 35 
> 50 
-60 to -40 
State 2 28.6 
35 to 50 
-5 to 15 State 3 23.8 
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5.7.7.4 Dependence of computed conductance of cis GMG-SMJ snapshots on 
the dihedral angle () and the distance of H-bond 2 (d2) 
 
Figure S5.13. Conductance analysis for the MD simulations of cis GMG-SMJ snapshots. (a) 
Dependence of computed conductance on dihedral angle (). (b) The corresponding H-bond 1 distance 
(d1) and H-bond 2 distance (d2) for the selected GMG-SMJ snapshots. (c) Distribution of the  over the 
course of simulations. (d) Dependence of computed conductance on d2. (e) The corresponding  and d1 
for the selected GMG-SMJ snapshots. (f) Distribution of d2 over the course of simulations. 
Table S5.4. Statistical analysis of H-bond 1 distance (d1) for the cis GMG-SMJ. 
Distance (Å) Conductance state Occupancy rate (%) 
< 1.80  State 3 5.7 
1.80 to 2.10 State 2 65.9 
> 2.10  State 1 28.4 
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6.1 Conclusion 
The research presented in this thesis provided a thorough investigation of the relationship 
between structure and function using model peptides, due to the complex nature of proteins. We 
have demonstrated that an ability to control structure will allow for the modulation of 
antibacterial properties using a photopharmacological approach and hypoxia-activated prodrug 
strategy. The regulation of peptide activity offers an opportunity to mitigate off-target side 
effects, and in the context of an antibiotic, the development of resistance. Moreover, we 
unravelled the intrinsic dynamic properties corresponding to specific structural changes within 
each isomer of a photoswitchable cyclic peptide using the electrically characterized single-
molecule junction technique. This research deepens our understanding of the structure and the 
intrinsic dynamic behavior of peptides, with these fundamental properties potentially extending 
to proteins.  
6.2 Further studies 
In chapters 2-3, the regulation of antibacterial activity through the photochemical control of an 
azobenzene photoswitch was demonstrated. However, cytotoxicity tests on human cells and 
pharmacokinetics studies are required to fully evaluate the efficacy of the peptide mimetics to 
function as potential antibiotics in vivo. Numerous challenges associated with light delivery 
must be overcome to exploit the full potential of photopharmacology. Light does not penetrate 
tissue efficiently due to melanin pigmentation of the skin and the absorption of biomolecules, 
such as heme and flavoproteins.1 Nevertheless, recent advancements in biomedical engineering 
research have proposed innovative methods to allow subdermal light delivery using 
optoelectronic implants and optical fibers (Figure 6.1).2 Future work on chapters 2-3 may 
involve attachment of the photoswitchable antibacterial peptides onto optical fibers, where light 
from an external source can be transmitted through the fibers to enable photoswitching between 
two peptide conformations to modulate the antibacterial activity. Moreover, the intensity and 
wavelength of light, location, and time of irradiation can then be tuned with spatiotemporal 
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precision. These new technologies can potentially improve precision sensing, diagnosis, and 
point-of-care treatment for bacterial infections.  
 
Figure 6.1. New technologies for light delivery. (a) A wireless optoelectronic implant to control bladder 
function in rats. (b) A microscale injectable light-emitting diode to allow subdermal light delivery in the 
brains of mice. (c) Multifunctional optical fibers to probe neuronal activity. (d) A wireless photonic 
device that emits light for photodynamic therapy of tumors. (Figure adapted from Morstein et al.1) 
Chapter 4 successfully demonstrated the liberation of an active antibacterial agent on reduction 
under conditions that mimic hypoxia, however, the activation of the prodrug under tissue 
hypoxia remains to be done. Moreover, the dose-limiting toxicity and mechanism of activation 
of the bioreductive prodrug need to be investigated to examine the clinical relevance of the 
hypoxia-activated prodrug strategy for bacterial-infected tissue. 
Chapter 5 provided a step towards multi-modal bio-inspired nanodevices by unravelling the 
structural dynamic behavior of a photoswitchable cyclic peptide that can be interconverted 
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between a well-defined cis isomer and an ill-defined trans isomer. Our photoresponsive single-
molecule device offers the capacity to modulate conductance, which paves the way for the 
realization of photocontrollable bio-inspired molecular electronic components. Future work on 
this research could focus on improving device stability and optimizing the device fabrication to 
probe the fundamental molecular properties, such as molecular structure, dynamics, and 
reactivity. This bottom-up approach is required to solve the challenge of miniaturizing 
components in conventional silicon electronics.3 
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